Breast cancer is the most frequent type of malignancy in women worldwide, and drug resistance to the available systemic therapies remains a major challenge. At the molecular level, breast cancer is heterogeneous, where the cancer-initiating stem-like cells (bCSCs) comprise a small yet distinct population of cells within the tumor microenvironment (TME) that can differentiate into cells of multiple lineages, displaying varying degrees of cellular differentiation, enhanced metastatic potential, invasiveness, and resistance to radio- and chemotherapy. Based on the expression of estrogen and progesterone hormone receptors, expression of human epidermal growth factor receptor 2 (HER2), and/or BRCA mutations, the breast cancer molecular subtypes are identified as TNBC, HER2 enriched, luminal A, and luminal B. Management of breast cancer primarily involves resection of the tumor, followed by radiotherapy, and systemic therapies including endocrine therapies for hormone-responsive breast cancers; HER2-targeted therapy for HER2-enriched breast cancers; chemotherapy and poly (ADP-ribose) polymerase inhibitors for TNBC, and the recent development of immunotherapy. However, the complex crosstalk between the malignant cells and stromal cells in the breast TME, rewiring of the many different signaling networks, and bCSC-mediated processes, all contribute to overall drug resistance in breast cancer. However, strategically targeting bCSCs to reverse chemoresistance and increase drug sensitivity is an underexplored stream in breast cancer research. The recent identification of dysregulated miRNAs/ncRNAs/mRNAs signatures in bCSCs and their crosstalk with many cellular signaling pathways has uncovered promising molecular leads to be used as potential therapeutic targets in drug-resistant situations. Moreover, therapies that can induce alternate forms of regulated cell death including ferroptosis, pyroptosis, and immunotherapy; drugs targeting bCSC metabolism; and nanoparticle therapy are the upcoming approaches to target the bCSCs overcome drug resistance. Thus, individualizing treatment strategies will eliminate the minimal residual disease, resulting in better pathological and complete response in drug-resistant scenarios. This review summarizes basic understanding of breast cancer subtypes, concept of bCSCs, molecular basis of drug resistance,
INTRODUCTION

Breast cancer (BC) is the most frequent type of malignancy in women worldwide. BC has now eclipsed lung cancer as the leading cause of global cancer incidence in 2020, with an estimated 2.3 million new cases, representing 11.7% of all cancer cases (1). Drug resistance in BC patients appears to be the major challenge in breast cancer research. Despite significant advances in BC treatment, many patients with malignant BC experience aggressive disease progression due to treatment, many patients with malignant BC experience aggressive disease progression due to de novo and acquired drug resistance. De novo resistance occurs even before drug exposure, while acquired resistance emerges from initially drug-sensitive tumors. The mechanisms associated with de novo drug resistance significantly contribute to failure to eradicate the residual disease, thus facilitating the development of acquired drug resistance (2).

The failure of the current treatment therapies as well as the high mortality in metastatic BC patients is highly attributed to the existence of therapy-resistant breast cancer stem-like cells (bCSCs). The emerging concept of CSC origin supports the hierarchical organization of CSC-like cells, sitting at the top of the hierarchy, having the unique ability to give rise to diverse lineages of cancer cells that forms the tumor. Although the CSC-like cells occupy only a very minor fraction of the total tumor mass (around 2%), they are mainly responsible for establishing the intratumor heterogeneity (3). The concept of “tumor heterogeneity” refers to the genetic variation existing between tumor cells within and across the BC patients. According to the CSC concept, the CSC-like cells possess three main characteristics: (1) potent tumor initiation potential to regenerate the tumor, (2) self-renewal feature in vivo that would inevitably allow them to form a phenotypically indistinguishable heterogeneous tumor, when transplanted in secondary or tertiary recipients, and (3) finally, they must reflect the differentiation ability so that they can re-establish a phenocopy of the original tumor. Hajj et al. first identified and isolated the bCSCs (CD44+CD24−/lowLineage−) from the phenotypically diverse population of BC cells. This fraction of breast tumor cells can form a new tumor with additional CD44+CD24−/lowLineage− bCSCs along with phenotypically different nontumorigenic cells (4). If the therapy in question fails to specifically target and kill the bCSCs, they would persist as tumor-resistant tumors, which can regenerate tumors in the future. Frequently, the bCSCs overexpress the drug efflux transporters and spend most of the time in the nondividing cell-cycle phase (G0) to escape from the conventional therapies (5). Hence, targeting the bCSCs in any subtype, such as luminal A, luminal B, human epidermal growth factor receptor 2 (HER2)-enriched, and triple-negative (TNBC), is the key strategy to conquer therapeutic resistance in BC. The complex communication between bCSCs and the stromal cells; resistance to chemotherapeutic drugs (paclitaxel, anthracycline, platinum), endocrine therapies (tamoxifen, fulvestrant), and HER2-targeted drugs (trastuzumab, lapatinib); rewiring of hedgehog (Hh), Notch, Wnt/β-catenin, and phosphoinositide 3-kinase (PI3K)/Akt/mTOR signaling networks; and enhancing DNA repair mechanism, contribute to the overall drug resistance in bCSCs (6).

MicroRNAs (miRNAs) also add another dimension to the complexity of BC disease progression and therapeutic resistance, through maintenance of the bCSC population. MiRNAs are a group of small noncoding RNAs (ncRNAs) that influence the expression of their target genes at the posttranscriptional level by binding to the 3′-untranslated regions (3′-UTR) of mature mRNA transcripts. Two different types of miRNAs—tumor suppressor miRNAs (miR34, Let-7, miR30, miR200 family, miR600) and Onco-miRs (miR-22, miR155, miR181, miR221/222 cluster)—have been identified in bCSCs, having either tumor-suppressive or oncogenic functions, respectively. Interestingly, miRNAs have been implicated in the regulation of many different signaling networks, contributing to the development and maintenance of bCSCs (3, 7). Moreover, locoregional tumor burden along with the metastatic patterns in BC patients also influence the efficacy of the treatment strategies. In the case of early-stage BC, the tumor is restricted in the breast or local axillary lymph node, and the success rate for relapse-free survival is around 70%–80% (8). However, in the case of advanced BC, where metastatic dissemination from the primary tumor site leads to the re-establishment of secondary tumors involving other organs like lung, brain, liver, and bones, complete cure is not possible. In that scenario, much emphasis is given to prolonging the patient survival to exert a low degree of treatment-associated cytotoxicity to improve the quality of life.

Due to the lack of specific molecular targets in TNBC and increased resistance to the anti-HER2 therapies in HER2+ breast tumors, cytotoxic chemotherapy is the common alternative for treating these two most resistant subtypes of BC. However, there is an increasing search for therapeutic strategies that would sensitize the drug-resistant bCSCs to programmed cell death. Immunotherapy, based on the immune checkpoint inhibitor molecules (ICIs), specific for programmed cell death protein 1 (PD-1), programmed death ligand 1 (PD-L1), and CTLA-4, which are either administered as a single agent or in combination with either a humanized monoclonal antibody, such as trastuzumab, in HER2+ BC settings, or any other chemotherapeutic drug in the TNBC scenario, have been the recent candidates in clinical trials (8). Other immunotherapy approaches like the chimeric antigen receptor T-cell (CAR-T) therapy, dendritic cell (DC) vaccine, and oncolytic viral therapies, specific for bCSC immune targeting, are also gaining significant momentum in recent years (9). Nanoparticle-based
bCSC-targeting platform is also appearing as an upcoming approach to deliver small molecules, antibodies, and miRNAs to affect the signaling networks implicated in bCSC self-renewal and differentiation; interfering with drug-efflux transporters; and targeting bCSC metabolism (10). In this review, we focused on the mechanisms of resistance to chemo-, endocrine, and targeted therapies, the contribution of bCSCs in exerting drug resistance, and the factors influencing bCSC-mediated drug resistance and, finally, we emphasized the alternative forms of upcoming treatment platforms to overcome CSC-related drug resistance in BC patients.

**BREAST ARCHITECTURE, BC SUBTYPES, AND ADVANCEMENT OF TECHNOLOGIES TO IDENTIFY BC**

The breast architecture mainly involves glandular tissue including the breast lobes and ducts, supportive fibrous connective tissue, and fatty tissues that largely fill in the gaps between the glandular and fibrous tissues. An adult woman’s breast consists of 15–20 lobes, each lobe further containing 20–40 lobules. The lobules resemble a grape-like structure, where each of the lobules is attached to a small milk duct, and finally these small ducts join, eventually forming a larger collecting duct. There are around 10 ductal systems present in each breast that finally open at the nipple. A cross-section of a milk duct shows a basement membrane layer, the basal or myoepithelial layer, and the luminal or epithelial layer, from outside to inside (Figures 1A–C). In 20%–25% of cases, the tumor is restricted at the site of its origin (in situ or preinvasive); whereas, in 75%–80% of cases, the tumors are malignant (invasive) whereby the malignant cells invade the basement membrane and penetrate the stroma.

**Histological and Molecular Subtypes**

BCs are generally divided according to histological grade and stage, which define the aggressiveness and metastatic potential of the tumor. Histologically, the breast tumors are distinguished into preinvasive and invasive subtypes involving the ductal and lobular compartments. Ductal and lobular subtype is classified as ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), lobular carcinoma in situ (LCIS), and invasive lobular carcinoma (ILC), respectively (Figures 1D–H) (11). At the molecular level, breast tumors are categorized into 4 main subtypes, based on the presence/absence of markers that include estrogen receptors (ER), progesterone receptors (PR), and HER2, as well as their proliferative index according to Ki67 expression (12). These molecular subtypes include TNBC (ER−, PR−, HER2−), HER2-enriched (ER−, PR−, HER2+), luminal A (ER+ and/or PR+, but HER2−, Ki67 <14%), and luminal B (ER+ and/or PR+, HER2+ or HER2−, Ki67 >14%) (refer to Figure 1I). ER+ breast tumors are targeted using selective estrogen receptor modulators (SERMs), aromatase inhibitors, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors, and ER degraders also called selective estrogen receptor downregulators (SERDs) (13). HER2-enriched breast tumors are candidates for HER2-targeted monoclonal antibodies. However, TNBC accounts for the most therapy-resistant subtype of heterogeneous basal-like tumors (15%–20% of all breast tumors), which frequently reflects a high mutational burden including tumor suppressor p53 (TP53 gene, 74.5%–82.8%), breast cancer type-1 and/or type-2 susceptibility gene (BRCA1, 1.96%–21.55%; BRCA2, 1.63%–18.10%), and phosphatidylinositol 3-kinase catalytic alpha polypeptide (PI3KCα, 8.6%–23.2%) (9, 14–16). However, another compelling piece of evidence from Maristany et al. suggests the concept of phenotypic switching between BC molecular subtypes, as evident from the gene expression studies before, during, and after neoadjuvant therapy with lapatinib and trastuzumab in HER2+/HER2-enriched tumors of the PAMELA trial and BC cell lines (17). Dual blockade of HER2 pathway in HER2-enriched settings leads to a subtype switching to a low-proliferative luminal A phenotype both in the patients’ tumor samples and in vitro models. Strikingly, this subtype switching from HER2-enriched to luminal A phenotype increased the sensitivity toward CDK4/6 inhibitors; although, this switching is reversible upon stopping the anti-HER2 treatment. Moreover, integrated analysis of copy number and gene expression studies of 2,000 breast tumors by Curtis et al. reveals the existence of novel molecular stratification among the BC population, resulting from the impact of somatic copy number aberrations (CNAs) on the transcriptome (18). A similar study of somatic CNAs revealed an advanced stratification of BC cases into integrative clusters and prototypical patterns of single-nucleotide variants, shaping the clinical courses and response to BC therapies (19). Therefore, in addition to the conventional BC molecular subtypes discussed above, the genomic and transcriptomic architecture of BC samples further add another dimension, yielding novel BC subgroups with distinct clinical outcomes. Moreover, the emerging evidence on the inter- and intratumoral heterogeneity within a breast tumor not only acknowledges the probability that multiple different BC subtypes can coexist within a single tumor but also demonstrates that plasticity between divergent subtypes is possible rather than being static (20). Interconversion between the different subtypes within a breast tumor contributes to disease progression, metastasis, and therapeutic resistance. Therefore, therapeutic decision making must be designed based on the genomic and transcriptomic inputs along with the changing molecular phenotypes even in an individual patient’s tumor.

**Solid Tissue Biopsy and Liquid Biopsy**

Solid tissue biopsy is the standard method of choice in clinical oncology that provides information on tumor histology, molecular profiling and subtyping, and biomarkers targeted for treatment planning (21). However, it does not reveal the complete genomic landscape of the tumor, as the tissue is collected from a specific biopsy area. The heterogeneous nature of the tumor is validated when tumor cells collected from multiple regions from a single patient are subjected to exome sequencing, ploidy profiling, and chromosome aberration analysis. Gerlinger et al., for example, noted that approximately
63%–69% of the mutations observed in tumor tissue obtained from a single biopsy derived from the same patient are not homogeneous throughout the tumor. This observation strongly indicates the importance of "multiregion biopsy" for the diagnosis of cancer (22).

To bypass this limitation, in 2020, the Food and Drug Administration (FDA) approved the use of "liquid biopsy" where DNA from circulating breast tumor cells (ctDNA) shed from the primary tumor site is isolated from the patient's blood and then subjected to microfluidic-based single-cell transcriptional profiling (23, 24). CtDNAs released into the systemic circulation can be theoretically defined as an admixture of tumor DNA samples from different metastatic sites, thus fully reflecting the tumor heterogeneity. A very recent work from Kingston et al. represents the application of plasma ctDNA sequencing to define the genomic profile of metastatic BC in 800 patients in the plasmaMATCH trial (25).

With this novel approach, diverse resistance mutations including enrichment of HER2 mutations in HER2+ tumors, ESR1 and MAPK pathway mutations in ER+ HER2– tumors, and multiple PI3KCA mutations in ER+ tumors, have been successfully demonstrated. Particularly, this study utilizes the ctDNA analysis platform in a large clinical trial to denote the subclonal diversification of pretreated advanced BC, categorizing unique mutational processes in ER+ BC and identifying novel therapeutic directions. This noninvasive methodology enables the detection of early stages of BC, monitoring of treatment efficacy and therapeutic resistance, and identification of minimum residual disease (MRD) and risk of relapse (24, 26). Circulating tumor RNAs are also released into the bloodstream of BC patients, which provides another analytic platform through the liquid biopsy method (27).

Next-generation sequencing (NGS) is also increasingly applied for high-throughput BC mutational profiling (28, 29).
**BCSCs AND DRUG RESISTANCE**

BCSCs can escape the conventional therapies through adaptation to several strategies, where the breast cancer stem-like cells can remain dormant or “quiescent”, turn off the apoptotic pathways, and increase DNA repair mechanisms, along with expelling chemotherapy (chemo) drugs out of the cell, manipulating TME, and managing the intracellular load of reactive oxygen and nitrogen species (ROS and RNS) (30). Although the dormant bSCs maintain themselves in the G0 state, they still retain the ability to enter the cell division cycle in response to mitotic stimulation (31). As chemotherapy and radiation therapy exclusively target the proliferating fraction of tumor cells, the bSCs can evade systemic therapies, and in turn, develop drug resistance. Thus, drug resistance confers the bSCs with a selective advantage over the non-CSCs that supports the resistance. This observation strongly proposes that distinct episodes of genetic/epigenetic modifications can occur in the tumor, contributing to tumor heterogeneity, varied dissemination, and drug resistance potential (40). Treatment with the available chemotherapeutic drugs can kill the nonstem-like tumor cells while sparing the drug-resistant bSCs, allowing them to survive, which eventually repopulate and develop into a tumor, leading to distant metastasis (refer Figure 2C). Therefore, treating a hierarchical tumor with some therapeutic agents that can specifically target and eradicate bSCs can be the only option to get rid of CSCs and tumor recurrence. However, even if the CSC fraction is eliminated out of the TME, the remaining tumor cells may undergo phenotype reversal to replenish the CSC-like population and lead to tumor regrowth (10). Moreover, a failed radiotherapy can stimulate the transition of dormant CSCs into the “awakened state”, whereby they can enter the cell cycle and start proliferating (41).

**Characterization of bSCs**

Since bSCs are phenotypically different from the rest of the cells present within TME, bSCs can be identified and sorted based on some classical bSC-specific markers like CD44, CD133, aldehyde dehydrogenase 1 (ALDH1) activity, epithelial cell adhesion molecule (EpCAM), CXCR4, ABCG2, CD34, CD49f, CD90, CD61, and breast cancer resistance protein (BCRP). However, due to the low specificity of these markers, a combination of CSC-like markers is frequently used. However, the combination of a high CD44/CD24 and ALDH1+ is considered to be the most accurate and consistent way of defining bSCs (42).

**CD44**

CD44 is a cell-surface hyaluronan acid (HA) receptor that contains an HA-binding site in its extracellular domain. Notably, HA is the major component of ECM. Hence, the CD44-HA interaction not only contributes to the cell adhesion to ECM components but also to tyrosine phosphorylation of cytoskeletal proteins, activation of RhoA/RhoG, Rac1, and Cdc42, fueling invasion and metastasis (43). Activation of these signaling pathways is essential for actin

---

**How the bSCs Originate Within a Tumor (Clonal Versus Stem Cell Model)**

There has been a great deal of debate on how CSCs originate. Clonal evolution theory and the cancer stem cell theory are the two most popular theories that shed light on the origin of this CSCs. Apart from this, CSCs are thought to be one of the determining factors establishing intratumoral heterogeneity, and both clonal evolution theory and stem cell model account for the same (37). The clonal evolution model holds an example of a nonhierarchical model where individual tumor cells are thought to undergo stochastic genetic/epigenetic changes as a function of time and serves as the platform for adaptation and selection of the fittest clones (38). Thus, each cell gets the chance to become tumorigenic or drug resistant if it accumulates enough episodes of genetic/epigenetic modifications. These changes contribute to intratumoral heterogeneity as a result of natural selection and evolution of bSCs with better survival fitness, where those clones will expand and survive, out-compete the other nontumorigenic clones with less fitness, eventually making them extinct. This landmark theory was proposed by Peter Nowell in 1976 (39). Furthermore, these clones may change spatially and temporally and develop into a complex subclonal architecture, contributing to tumor heterogeneity. However, the dynamic CSC model represents a hierarchical model, which holds that only the CSC-like cells can develop a tumor, based on their infinite self-renewal and tumorigenic properties (refer to Figure 2A). According to this model, a CSC-like cell can either symmetrically divide giving rise to two new CSCs or can asymmetrically divide into a differentiated daughter cancer cell and a CSC (refer to Figure 2B). Hence, CSCs contribute to intratumoral heterogeneity through a differentiation program generating a range of distinct cell types within a tumor. However, this differentiation hierarchy is not only a one-way route but can also be reversible or plastic where the terminally differentiated pool of cancer cells can reverse their phenotype and acquire CSC-like properties through a dedifferentiation program, termed as "phenotype reversal". Recent studies also indicate that different subpopulations of CSCs with varying biochemical, biophysical, and metabolic signatures may exist within a tumor, contributing to tumor heterogeneity, varied dissemination, and drug resistance potential (40). Treatment with the available chemotherapeutic drugs can kill the nonstem-like tumor cells while sparing the drug-resistant bSCs, allowing them to survive, which eventually repopulate and develop into a tumor, leading to distant metastasis (refer Figure 2C). Therefore, treating a hierarchical tumor with some therapeutic agents that can specifically target and eradicate bSCs can be the only option to get rid of CSCs and tumor recurrence. However, even if the CSC fraction is eliminated out of the TME, the remaining tumor cells may undergo phenotype reversal to replenish the CSC-like population and lead to tumor regrowth (10). Moreover, a failed radiotherapy can stimulate the transition of dormant CSCs into the “awakened state”, whereby they can enter the cell cycle and start proliferating (41).
cytoskeletal remodeling, actin filament assembly, tumor cell migration, and invasion. CD44 is overexpressed in bCSCs and interestingly involves the Src kinase family proteins to initiate BC progression via Twist signaling (44). Moreover, CD44 contributes to chemoresistance since it upregulates the expression of multidrug resistance receptors by activating Nanog (45).

CD133
CD133 is another bCSC-specific marker found to be enriched in basal-like, HER2+, luminal, and TNBC subtypes. CD133-high bCSCs have been documented in tumor cell proliferation, vasculogenic mimicry, invasion, metastasis, and drug resistance (6). Croker et al. identified CD44+CD133+ALDHhigh bCSC-like cells as crucial mediators of BC metastasis (46). BRCA1-associated murine breast tumors consist of CD44+/CD24− and CD133+ cells with bCSC-like features, showing a greater intrinsic colony-forming potential that can regenerate breast tumors in NOD/SCID mice (47). Interestingly, CD133-high bCSCs augments endocrine resistance in metastatic BC via the IL-6/Notch signaling (48). Xenograft initiating CD44+CD49fhighCD133/2 high cells display self-renewal in vivo and greater tumorigenicity in ER− breast cancer (49).

ALDH1
Aldehyde dehydrogenase 1 is a member of NAD(P)+-dependent cytosolic isoenzymes, which is critically responsible for the

---

**FIGURE 2** | The origin of breast CSCs within a tumor. (A) Dynamic cancer stem cell (CSC) model of cancer cell plasticity showing switching between CSC-like state and differentiated cancer cell states (non-CSCs) through differentiation and dedifferentiation pathways. (B) Establishment of intratumor heterogeneity in breast cancer, resulting from symmetric and asymmetric cell divisions of breast CSCs. (C) Representative images of classical chemotherapy, CSC-targeted therapy, phenotype reversal, and combination therapy for target killing of breast cancer stem-like cells from TME.
oxidation of retinol to retinoic acid, required for early differentiation of stem cells. ALDH1 is a general marker of both human normal mammary stem cells and malignant mammary stem-like cells, and high ALDH1 activity is an independent predictor of poor clinical outcome and survival of BC patients (50). Interestingly, only a fraction of CD44+CD24−/low bCSC BC cells are ALDH1+ and display the highest tumorigenic potential, when compared with ALDH1− population (50). Moreover, ALDHhighCD44+CD24− and ALDHhighCD44+/CD133+ bCSCs, isolated from MDA-MB-231 and MDA-MB-468 cell lines, respectively, demonstrated enhanced growth, adhesion, migration, colony formation, and invasion profile, compared with ALDHlowCD44−/low cells (46). Therefore, inhibition of ALDH activity can effectively reverse doxorubicin/paclitaxel resistance of ALDHhighCD44+ human bCSCs (51). ALDH− bCSCs with an increased expression of interleukin-1 receptor (IL1R1) are enriched following antiestrogen therapy and held responsible for the treatment failure (52). Hence, targeting the ALDH+IL1R1+ bCSCs is crucial to reverse the drug resistance exerted by antiestrogens.

EpCAM
EpCAM is a glycosylated type 1 glycoprotein, expressed by human epithelial cells, and functions as an oncogenic signal transducer (53). Al-Hajj et al. showed that EpCAM+CD44+CD24−/lowLineage− fraction had a >10-fold higher frequency of tumor-initiating cells compared with EpCAM−CD44+CD24−/lowLineage− fraction (4). Interestingly, EpCAM overexpressing BC cells can withstand greater radiation stress compared with EpCAMlow cells (54). Hence, EpCAMhigh BC cells retain the ability to form a higher number of mammospheres. Activation of the AKT pathway is also observed in EpCAM overexpressing ZR-75-1 breast cancer cell line, compared with parental cell line. Moreover, EpCAM overexpression also reflects a higher percentage of cells with an E/M hybrid state, encouraging EMT, invasion, and metastasis. EpCAM+ circulating tumor cells isolated from primary human luminal BC patients’ blood contain metastasis-initiating cells, leading to bone, lung, and liver metastasis in mice (55). Since survivin has a crucial role in bCSC chemoresistance, EpCAM aptamer-mediated survivin silencing can sensitize bCSCs to doxorubicin and reverse chemo-silencing (56).

CXCR4
The chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) is considered to be a prognostic marker of bCSCs. The metastatic cascade is initiated via a series of sequential steps that include local invasion and intravasation (transendothelial migration) of cancer cells from the primary tumor site into the circulation, followed by extravasation at distant sites and subsequent organ colonization (homing) (57). Cancer cells at the growing front of the tumor undergo EMT, which degrades the underlying basement membrane and ECM before intravasation. The CXCR4 receptor and its ligand, CXCL12 (SDF-1) play an important role in the dissemination of BC cells from the primary site, transendothelial migration, and eventually trafficking and homing of bCSCs. Chemokines are 8–12-kDa chemoattractant cytokines that contribute to differentiation, cell activation, and trafficking. Notably, the chemoattractant CXCL12 provides directional guidance to CXCR4+ bCSCs toward the secondary metastatic site and initiates metastasis (58–60). Hence, targeting the CXCR4-CXCL12 signaling axis could serve as an alternative approach to restrict bCSC-driven drug resistance. Additionally, CXCR4+ bCSCs show a higher vimentin/E-cadherin ratio, indicating EMT. Interestingly, CXCR4 inhibition can enhance the infiltration of cytotoxic T-cell lymphocytes (CTLs) and improve the responses to immune checkpoint blockers in metastatic BC (61). A quantitative phosphoproteomic study by Yang et al. validated the importance of CXCR4-SDF1 signaling in bCSCs and also identified several important signaling pathways in bCSCs, downstream of CXCR4-SDF1 (62).

Evidence on Therapy-Induced bCSC Enrichment and Drug Resistance
Several studies indicate evidence on bCSC enrichment postanticancer therapy, although the underlying molecular mechanisms leading to bCSC enrichment are largely unknown. Since radiation treatment preferentially kills actively proliferating non-CSCs, there is a natural enrichment of bCSCs posttherapy. Furthermore, radiation can induce reversible transformation between CSC and non-CSC phenotype such that more CSC-like cells, with an increased level of stemness and tumorigenic potential, are generated from both normal stem cells as well as neoplastic nonstem-like cells, which ultimately leads to an increase in the absolute number of bCSCs within TME (41, 63, 64). It is hypothesized that in advanced cancer cases, the majority of the CSCs remain “dormant”, thus remaining unaffected by radiotherapy. Moreover, it is the unique potential of CSCs that can modify divisional dynamics, favoring symmetrical division, generating two identical CD44+CD24−/low daughter cells with higher radioresistance, postradiotherapy (65, 66). The number of tumor-initiating bCSCs also increases along with Notch upregulation, following a brief period of fractionated irradiation (66). Moreover, a study on non-CSCs isolated from the BC patients indicates that ionizing radiation (IR) reprograms the phenotype of differentiated BC cells and converts them into induced bCSC (i-bCSC). These i-bCSCs reflect a greater tumorigenic and mammosphere formation potential, along with a higher expression of stemness-related genes, OCT-4, Sox2, Nanog, and KIf4 (67). Furthermore, in response to IR, non-CSCs undergo radiation-induced EMT and show an increased migratory potential leading to metastasis and disease relapse, thus closely mimicking the CSC-like phenotype (68). Altogether, this evidence strongly suggests that acquisition of CSC phenotype by differentiated BC cells is an example of a direct effect of anticancer therapy, rather than a random event. Another study on glioma and breast cancer suggests that around one-third of the CSCs remain in dormancy and do not enter the cell cycle until challenged with IR (69). This refers to a mechanism whereby more “awakened CSCs” are generated from “dormant CSCs”. Moreover, radiotherapy favors oncogenic metabolism in CSCs upon their conversion from a slow-cycling “dormant” to “awakened” state, which increases their therapeutic resistance (68). Chemotherapy
treatment also enhances the percentage of CD44+CD24−/low BC cells, indicative of innate chemoresistance exerted by bCSCs (70). Hence, despite eradicating the CSCs from the tumor, antitumor therapies including chemo- and radiation therapy rather help the dormant bCSCs to survive by increasing their intrinsic resistance and finally leading to tumor recurrence. Recently, an intricate link between the dormant disseminated tumor cells (DTCs) and therapeutic resistance has been documented, in the course of metastasis (71). DTCs also spread via the metastatic cascade and enter the blood or lymphatic circulation (57). During circulation, the DTCs undergo a reversible mitotic arrest program, followed by a long period of dormancy, termed as “quiescence”, when they remain viable but do not increase in number (72). It is hypothesized that a percentage of breast DTCs are indeed bCSCs with long half-lives (73), capable of evading immune surveillance through expression of PD-L1 and show innately higher resistance toward standard radiation, chemo-, and even immunotherapy (74). Upon reaching the distant organs, DTCs infiltrate into the local tissue stroma, although they cannot form micrometastases until dormancy is over. This period is termed as “metastatic cancer dormancy” which reflects the period between the initial therapy and disease relapse. Once the dormant DTCs get adjusted to the new microenvironment, they “awaken” from their dormant state, gain the ability to re-enter the cell cycle, and proliferate, ensuing the metastatic outgrowth (72). Interestingly, ~62% of all deaths from BC happen after 5-year survival mark, emphasizing the contribution of dormant DTCs in disease recurrence (75). Several molecular targets, including integrin α5β1, β1, α2, αβ3, FAK, PKC, STAT3, and Cox1/2 have been identified to DTCs’ reawakening program, for which specific therapeutic agents are designed (72). Therefore, if the bCSCs could be targeted before they awaken from dormancy, metastatic dissemination and drug resistance can be potentially restricted.

Factors Contributing to bCSC Drug Resistance Against Conventional Therapeutic Drugs

Vasculogenic Mimicry

Vasculogenic mimicry (VM) is a recently defined pattern of tumor microvascularization that refers to the ability of cancer cells to organize themselves into vascular-like structures to procure nutrients and oxygen independently of normal blood vessels (76, 77). Unlike the concept of angiogenesis or vasculogenesis where the endothelial cells participate in blood vessel formation, VM particularly depends on the participation of highly aggressive tumor cells, having the endothelial phenotype, to form vessel-like structures (Figure 3A). VM has been reported in different types of solid aggressive tumors including BC (78–80). CD133+ breast CSCs reflect VM, with a higher expression of vascular endothelial-cadherin (VE-cadherin), along with an upregulated expression of matrix metalloproteinase, MMP-2, and MMP-9 in TNBC (81). Notably, both MMP-2 and MMP-9 are critical players in cellular plasticity and VM formation. According to Sun et al., it is the bCSCs that line the VM channels in breast tumor tissues from TNBC patients (82). Additionally, bCSCs produce more VM-related molecules like CD133 and ALDH1, to synergize VM formation (82, 83). However, cells participating in VM formation lack the classical endothelial marker CD31, and thus, administration of angiogenesis inhibitors does not affect VM formation. In this context, a phytocompound, thymoquinone (TQ), has been reported to exhibit an inhibitory effect on VM and promotes mesenchymal–epithelial transition (MET) in bCSCs derived from MDA-MB-231, in a dose-dependent manner. Moreover, CD44+CD24− bCSCs when incubated with TQ can interfere with rhodamine-123 efflux and decrease stemness. This observation indirectly denotes that thymoquinone relieves the drug-resistance properties of bCSCs (84). Mechanistically, TQ suppresses the PI3K and Wnt3a signaling, leading to the reduction of the p-Akt/Akt ratio, and has the potential to reduce the number of bCSCs.

Decreased Ferroptosis in bCSCs

Ferroptosis is an iron-dependent mechanism of regulated cell death, which is characterized by the intracellular accumulation of lipid-based ROS, ultimately resulting in the loss of membrane integrity (Figure 3B) (85). Notably, lipid-ROS is detoxified in a GPX4-catalyzed enzymatic reaction, which uses glutathione as a reducing agent. Hence, ferroptosis can be triggered either by inhibiting GPX4 enzymatic activity or depleting glutathione. Type I ferroptosis-inducing compounds, including sulfaflazine and erastin block the amino acid transporter required for cysteine import to synthesize glutathione. Type II drugs, such as RSL3, interfere with GPX4 peroxidase activity. Mechanistically, the execution of ferroptosis requires a high concentration of intracellular iron. Ferritin, the intracellular iron-storing protein, can release iron to initiate ferroptosis. The released iron can yield lipid-ROS in an autoamplifying manner. Ferroptosis can be inhibited by the presence of iron chelators and activated by transferrin and its receptor (86). Hence, sensitizing tumor cells to ferroptosis appears as a possible therapeutic approach for BC treatment. Notably, drug-tolerant BC cells show a dependency on the GPX4 activity, thus inhibition of GPX4 can potentially overcome BC drug resistance (87). Taylor et al. reported an array of ferroptosis-inducing small molecules that can selectively kill bCSCs with the mesenchymal phenotype in vitro (88). TNBC cells are highly susceptible to cysteine starvations, leading to ferroptosis and necroptosis, via the GCN2-eIF2α-ATF4-CHAC1 pathway (89). Since cysteine serves as the substrate for glutathione synthesis to prevent ferroptosis, depleting the pool of cysteine can sensitize BC cells to ferroptosis (89). Another synthetic derivative from salinomycin, ironomycin (AM5), can trigger cell death in bCSCs, both in vitro and in vivo, by sequestering iron in lysosomes, which further indicates that iron homeostasis plays a crucial role in bCSC survival (90). A novel nanoparticle, ferritin-bound erastin, and rapamycin (NFER) has shown robust ferroptosis-inducing properties by interfering GPX4 in 4T1 orthotopic BC mouse model (91).

Increased Autophagy in bCSCs and Drug Resistance

Autophagy is an evolutionarily conserved self-degradation process that recycles intracellular nutrients, growth factors, and
energy to sustain survival and cellular activities during stress like hypoxia, nutrient deprivation, and ischemia (92). Autophagy provides bCSCs with metabolic flexibility that becomes a prerequisite for their survival in oxygen- or nutrient-poor TME (93). Autophagy contributes to bCSC dormancy, stemness, maintenance, and drug resistance (94–96). Chaperone-mediated autophagy (CMA) and macroautophagy are two different modes of the autophagy process, documented in mammalian cells. Autophagy can elevate bCSC number, and thus develop drug resistance to conventional chemotherapies (97). Furthermore, autophagy-related genes (ATGs) such as ATG4A, ATG5, ATG12, LC3-B, and Beclin1 are expressed in dormant bCSCs, promoting bCSC survival and sustaining bCSCs over the progression of BC (96). Expression of Beclin1 is noted to be higher in mammospheres derived from BC cell lines, MCF-7 and BT474, compared with the adherent cultures (98). Moreover, the expression of lysosome-associated membrane protein type 2A (LAMP2A), involved in the CMA pathway, is augmented in the course of BC metastasis (99). Autophagy of cancer-associated fibroblasts (CAFs) also contributes to TNBC proliferation and progression. Notably, autophagy-relevant Beclin1 and LC3-II/I protein conversion levels are higher in CAFs, compared with the normal fibroblasts in TNBC (100). Since autophagy serves as one of the factors in malignant growth, inhibition of autophagy can suppress tumor growth. Pharmacological targeting of the autophagic flux with salinomycin can reduce bCSC-driven drug resistance, interfere with their stemness, and also compromise the bCSC tumorigenic potential (101).

**Enhanced Drug-Efflux in bCSCs**

CSCs often express a higher level of ATP-binding cassette (ABC) transporters that facilitate them to survive chemotherapy, aiding in the survival of drug-resistant CSCs (102). ABC transporters can efficiently expel cheemo drugs like anthracycline or taxanes out of the cells and can eventually lead to the acquisition of drug resistance phenotype in bCSCs (Figure 3C). This group of

**FIGURE 3** | Factors responsible for bCSC-mediated drug resistance against traditional anticancer therapeutics. (A) Concept of vasculogenic mimicry observed in breast CSCs leading to drug resistance. (B) Representative image of ferroptosis pathway involving generation of lipid-ROS in an iron-dependent manner, leading to oxidative cell death of tumor cells. (C) Increased drug efflux due to enhanced expression of ABC transporters in bCSCs, resulting in lower intracellular chemotherapeutic drug concentration. (D) Low ROS burden and enhanced DNA damage repair in bCSCs. (E) Restoration of T-cell activity by targeting immune-checkpoint molecules like PD-1, PD-L1, and CTLA-4 to reverse CSC-mediated immune escape in breast cancer. (F) Epithelial-mesenchymal transition (EMT) plasticity indicating the gradual transition of cancer cells from epithelial state to mesenchymal state and the transcription factors associated with the process.
The elongated cell-cycle window, that protects the DNA effectively (113). Both chemotherapy instability, CSC-like cells exhibit a highly dynamic DDR system and induction of EMT (111, 112). Therefore, the combined application of chemotherapeutic drugs and ABC inhibitors should be employed to kill the bCSCs (111).

Enhanced DNA Repair in bCSCs

Although cancer cells show a reduced DNA damage repair (DDR) mechanism and reflect many mutations and genomic instability, CSC-like cells exhibit a highly dynamic DDR system that protects the DNA effectively (113). Both chemotherapy drugs and radiotherapy can induce DNA damage. Mechanistically, radiotherapy contributes to DNA damage through the production of water-derived free radicals and ROS that avidly interacts with DNA, protein, and lipids. The generation of ROS, in turn, switches on the DDR pathway. However, in contrast to non-CSCs, CSCs have a low ROS burden and augmented DNA repair system (refer to Figure 3D). An increased level of ROS scavengers in CSCs maintains low levels of ROS that protect the CSCs from ROS-mediated DNA damage and apoptosis. The ROS scavenger, N-acetylcysteine, can restore both the CSC and EMT phenotypes (114). A novel compound, salinomycin, can effectively target the CSC niche and kill CD44highCD24−/−flow bCSCs as it upregulates the ROS levels (115). The radiore sistance property of CSC-like cells is linked with cell-cycle kinetics, which is reflected by a significant increase in the doubling time and Chk1/Chk2 basal activation level (116). The elongated cell-cycle window, therefore, offers more time to repair the genetic defects in CSCs. When the DNA defects are corrected, CSCs again enter into the cell cycle from the quiescent state and escape apoptosis. Therefore, targeting DDR could reverse therapeutic resistance.

Frizzled 5 (FZD5), a member of the FZD family, contributes to DDR, G1/S transition, proliferation, stemness, and chemoresistance in TNBC (117). FZD5 knockdown suppresses the expression of CD133, ALDH, EpCAM, and Oct-4, thus potentially overcoming chemoresistance and recurrence in TNBC. Likewise, CCR5 directs the DDR mechanism and bCSC expansion (118). CCR5 antagonists, vicriviroc and maraviroc, can substantially increase cell death caused by DNA-damaging chemotherapeutic drugs. MYC and MCL1 also cooperatively function in bCSC maintenance in TNBC patients via increasing ROS production and HIF-1α expression (119).

Immune Escape in bCSCs and Drug Resistance

CSCs are a crucial driver in immune evasion, metastasis, and drug resistance. Substantial evidence suggests a reciprocal interaction between CSCs and immune cells, and that CSCs adopt different strategies to circumvent immune attacks mediated by different immune cell types within TME. This, in turn, contributes to CSC expansion and mediate protumorigenic immune function, leading to CSC-specific avoidance of immune detection and destruction of immune cells. Tumor-associated macrophages (TAMs), tumor-associated neutrophils (TANs), myeloid-derived suppressor cells (MDSCs), DCs, tumor-infiltrating lymphocytes (TILs), B cells, natural killer (NK) cells, and T regulatory (Treg) cells, and proinflammatory cytokines secreted by these cells, are therefore crucial for maintaining an immune-resistant phenotype. Treatment of bCSCs with conditioned medium from TAMs results in an upregulated expression of Oct3/4, Sox2, Nanog, and ALDH1 activity (120). MDSCs also lead to the enrichment of bCSCs via IL-6/STAT3 and NO/Notch signaling, leading to the suppression of T-cell activation (121). The T-cell inhibitory molecule, PD-L1 is overexpressed on the bCSC cell surface, compared with their differentiated counterparts, and is dependent on PI3K/AKT and Notch signaling pathway (122). Interestingly, PD-L1 expression is upregulated in response to EMT induction and facilitates the immune escape of bCSCs (123, 124). Moreover, bCSCs are not only resistant to chemotherapy but also immunotherapy (125). Therefore, restoring the T-cell activity by manipulating immune checkpoint molecules, targeting either PD-1/PD-L1 (nivolumab/pembrolizumab) or CTLA-4 (ipilimumab) can be an effective strategy (Figure 3E). Also, immunosuppressive cytokines secreted by breast CSCs (IL-4, IL-6, IL-8, IL-10, and IL-13) result in therapeutic resistance, increased EMT, metastasis, and recruitment of immunosuppressive immune cell types like Treg and MDSCs (126). A high circulating level of IL-6 contributes to disease recurrence, tamoxifen resistance in luminal BC, and trastuzumab resistance in HER-2 enriched BC. Targeting IL-6 receptor with monoclonal antibody tocilizumab, hence, suppresses metastatic potential of bCSCs and enhances the cytotoxicity of cisplatin against TNBC (127).
resistance (128, 129). EMT inducers such as TGF-β and receptor tyrosine kinase (RTK) ligands modulate gene expression patterns through complex signaling networks (112). This results in the upregulation of transcriptional repressors such as Snail, Slug, Zeb1/2, Twist, and E47. This group of proteins, then, interacts with the promoter sequence of adherens junction protein, E-cadherin, recruits histone deacetylases (HDACs), and induces its chromatin condensation, leading to transcriptional repression of E-cadherin. EMT involves the dissolution of cell–cell adherens junction barriers, loss of apico-basolateral polarity of epithelial cells, along with increased expression of mesenchymal markers such as fibronectin and vimentin (Figure 3F) (128). This, in turn, aids in gaining motile characteristics of cancer cells post-EMT. Mani et al. indicated that when the EMT program is induced in immortalized human mammary epithelial cells through ectopic expression of Twist, Snail, or TGF-β treatment, the cells exhibited mesenchymal appearances, developed many stem-like properties, and had the potential to form mammary tumors in mice (128). Importantly, the metastatic cancer cells with mesenchymal-like features generated post-EMT, exhibited CD44high/CD24low signature, and formed mammospheres whereas CD44low/ CD24high cells could not. Al-Hajj et al. reported that disseminated BC cells found in pleural effusions are enriched in CD44highCD24−/low bCSCs (4). Interestingly, the EMT-associated emergence of bCSCs is induced by CD8+ T cells that stimulate dedifferentiation of BC cells into bCSCs (130). An increased expression of stroma cell-related genes, attributed to the EMT program, could be linked to drug resistance in BC (131). Hence, blocking the EMT program can eventually interfere with CSC maintenance and innate or acquired drug resistance (70). Therapeutic intervention of micro-RNAs can provide an additional strategy to disrupt the EMT-CSC deadly axis. Application of HDAC inhibitors and “differentiation-inducing” agents are also believed to fetch clinical benefits to BC patients.

**MECHANISM OF BCSC-MEDIATED DRUG RESISTANCE TO CANCER THERAPY**

**Resistance to Chemotherapy**

Chemotherapy involves chemo drugs given to the BC patients either intravenously or orally, along with other treatments like surgery, radiation, or hormonal therapy. Through the bloodstream, the chemo drugs reach the cancer cells and kill them. Adjuvant and neoadjuvant chemotherapies are two different modes of chemotherapies. In adjuvant chemotherapy (following surgery), the chemo drug is given to kill the cancer cells that have been left behind or could not be seen in imaging tests; whereas, in neoadjuvant chemotherapy, the chemo drug is given to shrink the breast tumor to reduce the requirement of extensive surgery. However, several lines of evidence indicate bCSC enrichment following exposure to chemo drugs, resulting in multidrug resistance (MDR). Here, we focus on the variety of chemo drugs (refer to Table 1), their mode of action, and potential mechanisms of chemo-resistance exerted by bCSCs.

**Paclitaxel Resistance**

Paclitaxel, a first-line therapeutic agent for the treatment of metastatic BC, is a microtubule-stabilizing agent. It interferes with microtubule dynamic instability at nanomolar concentrations, thus leading to G2/M mitotic arrest and apoptosis in BC cells (Figure 4A). Paclitaxel resistance seems to be one of the primary obstacles that lead to chemotherapeutic failure in BC. HER2/β-catenin pathway mediates paclitaxel resistance in BC cells, and hence suppression of the HER2/β-catenin signaling can overcome paclitaxel resistance (132). Penfluridol (PFL) treatments that suppress both HER2/β-catenin pathways significantly inhibit the survival of paclitaxel-resistant BC cells. Notably, paclitaxel resistance increases both CD44+CD24− bCSC content and sphere-forming ability in the paclitaxel-resistant SUM159 metastatic TNBC cell line (133). According to this report, dasatinib, an Src family kinase inhibitor, induces epithelial differentiation of mesenchymal TNBC cells and sensitizes TNBC cells to paclitaxel therapy through targeting bCSCs. An increased association of ALDH1 expression has been noted in paclitaxel-resistant BC patients (134). TNBC cell lines, such as MDA-MB-231, SUM-149, and SUM-159 show an enhanced activity of hypoxia-inducible factors (HIFs) and their target gene products, with chronic exposure to paclitaxel therapy. Furthermore, chemotherapy-induced HIF activation results in bCSC enrichment through IL-6 and IL-8 signaling and enhanced expression of MDR-1 (135). Hence, combinatorial therapies including HIF inhibitors along with paclitaxel chemotherapy are being tested in clinical trials to explore its efficacy in BC patients.

**Platinum Resistance**

Platinum-based chemotherapeutic drugs, such as cisplatin, oxaliplatin, carboplatin, nedaplatin, and lobaplatin are frequently the choice of drugs for treating advanced BC cases, including TNBC (136, 137). Mechanistically, platinum-based drugs interact with guanine and adenine nucleotides, forming platinum-DNA nonfunctional adducts, disrupting DNA double-helical structure, and eventually inhibiting cell division (Figure 4B) (138). However, drug resistance associated with platinum therapy and the numerous side effects that it causes have been a long-standing concern for BC patients. According to Sledge et al., only 47% of the BC patients with metastatic BC are partially sensitive to platinum therapy (139). Several lines of evidence indicate a crucial contribution of bCSCs in developing and maintenance of platinum resistance. In this context, a novel drug disulfluram (DSF) can reverse cisplatin resistance in different BC cell lines through inhibiting ALDH enzymatic activity and interfering with the expression of Oct4, Sox2, and Nanog in bCSCs. IL-6 secreted by breast tumor-derived mesenchymal stem-like cells (MSCs), augments cisplatin resistance via STAT3 signaling (140). Although neutralizing IL-6 can partially interfere with the IL6-STAT3 axis and reverse the cisplatin resistance, the specific role of bCSCs remains unclear. Notably, there is the active involvement of PI3K/akt/NF-kB signaling in enrichment as well as maintenance of breast CSCs. Cisplatin is known to stimulate transcriptional upregulation of PI3KCA, thereby triggering PI3K/akt signaling in platinum-
| Breast cancer subtype | Drug | Biological target (mechanism of action) |
|-----------------------|------|----------------------------------------|
| **Hormone positive**  |      |                                        |
| In clinical practice  |      |                                        |
| Tamoxifen             |      | Competitively inhibits interaction between ER and estrogen |
| Fulvestrant           |      | SERD, competitively inhibits estrogen to occupy ER, ER degradation |
| Aromatase inhibitors (AIs) (exemestane, anastrozole, letrozole) | | Blocks conversion of androgens to estrogens |
| Leuprolide            |      | Reduces production of estrogen and progesterone by the ovary by blocking effects of GnRH on the pituitary gland |
| Goserelin             |      | Luteinizing hormone-releasing hormone (LH-RH) agonist, stops LH production, blocks release of estrogen |
| Palbociclib (FDA approval: February 2015) | | CDK4/6 inhibitors for advanced stage BC along with letrozole |
| Ribociclib (FDA approval: March 2017) | | CDK4/6 inhibitors for advanced stage BC along with letrozole |
| Abemaciclib or verzenio (FDA approval: October 2021) | | CDK4/6 inhibitors for treatment of early-stage BC |
| Everolimus (FDA approval: July 2012) | | mTOR inhibitor, sensitizes hormone-receptor-positive BC to exemestane |
| **HER2 enriched**     |      |                                        |
| In clinical practice  |      |                                        |
| Trastuzumab           |      | Anti-HER2 mAb interacting with extracellular domain IV of HER2 |
| Pertuzumab            |      | Anti-HER2 mAb targeting HER2 extracellular domain II, inhibiting HER2 heterodimerization with EGFR, HER3, and HER4 |
| Lapatinib             |      | Tyrosine kinase inhibitor (TKI) targeting both EGFR and HER2, interacts at ATP-binding site of kinases |
| Ado-trastuzumab emtansine | | Anti-HER2 mAb conjugated with microtubule inhibitor emtansine |
| Margretuximab (FDA approval: December 2020) | | HER2-targeted antibody for metastatic HER2+ BC |
| Tucatinib (FDA approval: April 2020) | | HER2 inhibitor, used in combination with trastuzumab and capecitabine (Xeloda) in metastatic HER2+ BC |
| **In pipeline**       |      |                                        |
| Patritumab            |      | Anti-HER3 mAb in combination with trastuzumab and paclitaxel in phase I/II trial completed (NCT012760041) |
| Buparlisib with lapatinib and pilaralisib with trastuzumab | | Pan-class I PI3K inhibitor, combination therapy with fulvestrant, phase III trial (NCT01610284) |
| Lonafarnib            |      | Inhibits Ras activity, combination therapy with trastuzumab and paclitaxel, phase I completed (NCT000685757) |
| NeuVax + trastuzumab  |      | Immunotherapy for treatment of early-stage HER2+ BC; phase IIb trial (NCT02297698) |
| Ridaforolimus with trastuzumab | | mTOR inhibitors, phase II trial completed (NCT00736970) |
| Sirolimus with trastuzumab | | mTOR inhibitors, phase II trial completed (NCT00411788) |
| MK-2206               |      | Allosteric pan-Akt inhibitor; combination therapy with trastuzumab and lapatinib, terminated (NCT00965457) |
| **Triple-negative**   |      |                                        |
| In clinical practice  |      |                                        |
| Anthracyclines        |      | Topoisomerase II inhibitors, stabilize DNA breaks and ensuing tumor cell death |
| Taxanes               |      | Microtubule-stabilizing agent, stabilize GDP-bound tubulin in microtubule, G2/M arrest, cell death |
| Olaparib              |      | PARP inhibitor, blocks repair of single-strand DNA breaks by base excision repair (BER) system |
| Talazoparib           |      | PARP inhibitor |
| Bevacizumab           |      | Antiangiogenic mAb against VEGF bevacizumab + docetaxel anti-VEGF mAb |
| Atezolizumab (FDA approval: March 2019) | | Anti PD-L1 antibody as first-line therapy to locally advanced or metastatic PD-L1-positive TNBC patients |
| Pembrolizumab (FDA approval: October 2021) | | Anti PD-1 antibody for high-risk early-stage TNBC |
| Trodelvy (sacituzumab) (FDA approval: 2020) | | Trop-2 directed antibody and topoisomerase inhibitor drug conjugate for metastatic TNBC patients |
| **In pipeline**       |      |                                        |
| Cetuximab + cisplatin or carboplatin | | Anti-EGFR mAb for metastatic TNBC, phase II completed (NCT00463788) |
| Glembatumumab vedotin | | mAb-cytotoxic drug conjugate targeting glycoprotein NMB in TNBC, phase II completed (NCT01997333) |
| Dasatinib + cetuximab + cisplatin | | Src inhibitors, tested in TNBC cell lines |

The clinical trial number for the drugs in pipeline has been mentioned according to ClinicalTrials.gov.
resistant cells. However, a recent report emphasizes that mechanistically cisplatin leads to CSC enrichment in platinum-resistant cells through the NF-κB-TNF-α-PI3KCA loop (141).

**Anthracycline Resistance**
Anthracyclines, antibiotics extracted from *Streptomyces* bacteria, administered as broad-spectrum chemotherapeutic drugs in BC patients, are topoisomerase II inhibitors (Figure 4C) (142). Since, topoisomerase II modifies DNA topology by breaking or rejoining DNA double strands, inhibiting its catalytic activity stabilizes DNA breaks, eventually causing cell death. This class of drugs includes doxorubicin, daunorubicin, and epirubicin. Resistance to anthracyclines has been linked with multiple factors, such as the acquisition of MDR due to overexpression of drug efflux pumps and permeability glycoprotein-1, alteration of topoisomerase II activity, CSC enrichment, altered DNA repair, and metabolic reprogramming (143). A 4-day exposure to doxorubicin and paclitaxel, followed by a 2-day recovery, leads to significant enrichment of CD44highCD24−/low bCSCs (144). In this context, cardamonin, a small molecule, significantly prevents bCSC enrichment, when administered along with chemotherapeutic drugs, *via* downregulation of IL-6, IL-8, NF-κB, and STAT3 signaling (144). Knockdown of Annexin A3 also influences the drug sensitivity of bCSCs to doxorubicin *via* an upregulation of drug uptake, inhibits metastasis, and exhibits a change in heterogeneity and plasticity in bCSCs (145).

**Resistance to Endocrine Therapy**
Endocrine therapy is an effective mode of treatment for the ER+ BC cases that blocks ER signaling, depriving the growing tumor of estrogen (146, 147). ER signaling plays a crucial role in BC proliferation, invasion, and angiogenesis. Mechanisms, through which the endocrine therapy works (refer to Table 1), can be categorized into (1) SERMs, (2) aromatase inhibitors (AIs), (3) CDK4/6 inhibitors, and (4) SERDs (Figure 4D) (148, 149). SERMs function by sitting in the ER of breast tissues, blocking the estrogen from interacting with the ER, and hence the cells can no longer grow and multiply (150). Als work by blocking the function of the aromatase enzyme that converts androgen into estrogen (151). CDK4/6 inhibitors are generally used in combination with endocrine therapy to treat hormone-receptor-positive but HER-2 negative metastatic BC (152, 153). CDK4/6 is required by BC cells for cell-cycle division. BCSCs develop resistance to endocrine therapy in ER+ BC and are mainly responsible for the failure of endocrine therapy (154). Therefore, specific targeting of drug-resistant bCSCs could serve as a potential therapeutic strategy in overcoming hormonal therapy resistance.

**Tamoxifen Resistance**
ER-α-positive BC cases constitute around 70%–75% of overall BC incidence. Although, tamoxifen (TAM) has been the fundamental mode of endocrine therapy for the treatment of ER+ BC patients for the last three decades, acquired TAM resistance is frequently held accountable for the disease relapse (155). TAM competitively inhibits the interaction of estrogen ligand with ERs (Figure 4E). Most importantly, an increased proportion of bCSCs in advanced BC patients have a potential contribution to TAM resistance and breast tumorigenesis (156). Poorly differentiated breast tumors contain a higher percentage of CSC-like cells than well-differentiated breast tumors (157). TAM-resistant BC cells retain stem-like properties (158). Notably, TAM-resistant MCF-7 cells showed increased proliferation rate, enhanced mammosphere formation ability, increased mRNA expression of OCT-4, SOX-2, and CD133, and increased EMT signature, compared with wild-type MCF-7 cells (158). In a parallel study, Wang et al. indicated that TAM-resistant MCF-7 cells contain a higher proportion of CD44+CD24−/low bCSCs, exhibit lesser sensitivity to Adriamycin compared with wild-type MCF-7 cells, and express SOX-2 as a biomarker for TAM resistance (159). Serine phosphorylation, particularly at Serine 118, has been documented for activating the N-terminal transcriptional function of ER-α. SOX-2 can reprogram the non-genomic estrogen signaling and augment bCSC proportion through phosphorylation of ER-α at serine 118, making it hypersensitive to circulating estrogen (160). Phosphorylation, ubiquitination, and other posttranslational modifications play an important role in activating ER and its coregulators and can influence the sensitivity to different endocrine therapies (161). Therefore, inhibition of SOX-2 could restore the sensitivity of BC cells to TAM (162). Furthermore, ER splicing variants, including estrogen-related receptors (ERRs), and the recently identified estrogen receptor α-variant (ER-α36) are involved in TAM resistance and estrogen hypersensitivity (163). However, the contribution of ER-β in BCSC-mediated TAM resistance is still under investigation. Upregulation of different growth factors including HER2, epidermal growth factor receptor (EGFR), and insulin-like growth factor 1 receptor (IGF1R) has been documented in BC endocrine resistance, although direct evidence has been found in support of PI3K-mediated TAM resistance (164). Hence, targeting PI3K and IGF1R is considered a major therapeutic target to reverse TAM resistance in bCSCs. Different signaling pathways, such as Wnt and Notch, induce TAM resistance, promoting bCSC activity in TAM-resistant MCF-7 cells, while inhibition of these pathways could overcome TAM resistance (165, 166). A positive correlation has been noted between activation of Hedgehog (Hh) signaling and reduction in disease-free or recurrence-free survival in BC patients, which can even result in TAM resistance (167). The intervention of Hedgehog (Hh) signaling, thus, can potentially interfere with bCSC proliferation, migration, and invasion and reverse TAM resistance. Therefore, inhibition of Notch, Hedgehog (Hh), and Wnt/β-catenin signaling pathways should serve as another strategy to overcome TAM resistance in bCSCs.

**Fulvestrant Resistance**
Fulvestrant is a selective estrogen receptor degrader (SERD) administered in both first and subsequent lines of treatment in ER-α+ metastatic BC patients (149, 168). Fulvestrant competitively inhibits estrogen to occupy the ER, eventually promotes degradation of the receptor, and thus interferes with
estrogen signaling in breast tumor tissues (169). Unfortunately, there has not been extensive research done on fulvestrant resistance in BCSCs as well as the molecular mechanisms responsible for the resistance. Dysregulation of both G protein-coupled estrogen receptor-1 (GPER) and CDK6 are associated with fulvestrant resistance in BC (170). Notably, GPER-induced signaling is essential for the survival of BCSCs (171). Very recently, Kaminska et al. reported that cyclin E2 overexpression has been recognized as a biomarker for persistent fulvestrant-resistant metastatic BC and reduced disease-free survival (172). However, AI-resistant BC cells, having a higher proportion of BCSC-like cells and increased stemness, are inhibited by fulvestrant (173). Several signaling pathways, such as MEK/ERK, NF-κB, EGFR, PI3K/AKT, and β-catenin have been implicated so far to fulvestrant resistance in BC. MiRNA-221/222 confers estrogen-independent growth and fulvestrant resistance in BC through multiple signaling networks. Strikingly, miR-221/222 contributes to acquired fulvestrant resistance through activation of the β-catenin pathway, and miR-221/222 has recently been documented in CD44+/CD24−/low BCSCs (174).

**Aromatase Inhibitor Resistance**

AIs constitute the first-line therapeutic approach for the treatment of ER+ BC in postmenopausal women (175, 176). AIs deplete the circulating level of estrogen in the human body by interfering with estrogen biosynthesis through blocking aromatase activity (177). Hence, in the presence of AIs, estrogen production is inhibited, which slows down tumor progression in ER+ BC settings. When treating early-stage ER+ BC, AIs are frequently the choice of hormonal therapy over TAM due to the fewer side effects it causes. However, acquired AI resistance may develop in over 20% of early-stage BC patients and found to be inevitable in metastatic BC patients (178). Acquired AI resistance involves a switch from dependence on ER signaling to growth-factor-mediated signaling, such as HER2 signaling (179). Both cancer-cell intrinsic (enhanced activity of FGFR, ERBB2, and IGF1R and the downstream signaling of PI3K-AKT-mTOR and MAPK pathways) and extrinsic mechanisms (interaction of TME with other cell types) cumulatively coordinate the development and maintenance of AI resistance (180). AIs are classified into 2 subtypes—steroidal...
Involvement of bCSCs in therapeutic resistance (refer to Figure 4F). Therefore, we need to understand drugs, trastuzumab and lapatinib, significantly improved the clinical outcome in HER2-enriched BC, the associated drug resistance problem poses challenges to effective treatment. Resistance to anti-HER2 drugs occurs due to the presence of bCSCs in the tumor milieu that can remain resistant to trastuzumab after 1–2 years of treatment (185). Continuation application of trastuzumab in early stages of the disease, acquired resistance, however, to trastuzumab (Herceptin™) therapy plus chemotherapy in the early stages of the disease, acquired resistance, however, to trastuzumab after 1–2 years of treatment is a frequent event following metastasis (185). Factors like HER2 degradation, overexpression of other RTKs, mutation of PI3KCA (PI3K catalytic subunit p110α), and loss of Phosphatase and Tensin Homolog Deleted on Chromosome 10 (PTEN) tumor-suppressive function have been linked with trastuzumab resistance (186). Continued application of trastuzumab in HER2+ cells with loss of PTEN encourages EMT and transforms HER2+ BC to TNBC (187). Strikingly, these transformed cells frequently exhibit mesenchymal features along with mesenchymal-specific gene expression profile, although the parental HER2+ cells show epithelial morphology with epithelial-specific gene signature. Since bCSCs exhibit chemoresistance to small-molecule targeted therapy, exploring the mechanism of trastuzumab resistance must have clinical implications. bCSCs confer drug resistance by activation of different prosurvival pathways, such as PI3K/AKT, NFκB, and JAK/STAT pathways (188). Thus, CD44+CD24-/low bCSC phenotype serves as a prognostic factor for clinical outcome and predictive factor for poor trastuzumab response in patients with HER2+ BC. Importantly, PI3K/AKT/mTOR activation has been implicated in both de novo and acquired trastuzumab resistance (189). Since PTEN loss and mutation of PI3KCA lead to aberrant downstream activation of PI3K/AKT/mTOR pathway, which in turn sustains bCSC population, both the factors correlate with trastuzumab resistance (190). Therefore, combining PI3K/AKT/mTOR inhibitors along with HER2 targeting drugs to overcome trastuzumab resistance provides an active area of research. Pan-class I PI3K inhibitors, such as buparlisib and pilaralisib when administered with trastuzumab (189), lapatinib (191), or trastuzumab and paclitaxel (192), are proven to be safer and successful in HER2+ advanced stage BC patients. IL-6-mediated bCSC expansion is another independent mechanism resulting in trastuzumab resistance (36). Moreover, STAT3 activation also stimulates breast cancer stem-like properties resulting in HER2 overexpression and trastuzumab resistance (193). Hence, targeting JAK/STAT pathway or administering IL-6 receptor-targeted antibody should overcome the trastuzumab resistance by reducing the bCSC burden. Additionally, CD47 blockade with trastuzumab also eliminates HER2+ BC cells, overcoming trastuzumab tolerance (194).

**Resistance to Targeted Therapy**

HER2 is an oncogenic RTK, which is frequently genetically amplified or overexpressed in around 15%–20% of invasive BC cases (182). However, although the emergence of anti-HER2 drugs, trastuzumab and lapatinib, significantly improved the clinical outcome in HER2-enriched BC, the associated drug resistance problem poses challenges to effective treatment. Resistance to anti-HER2 drugs occurs due to the presence of bCSCs in the tumor milieu that can remain “hidden” from the activity of these drugs (111). Therefore, we need to understand the mechanisms responsible for the associated drug resistance followed by the application of anti-HER2 drugs to encounter the involvement of bCSCs in therapeutic resistance (refer to Table 1).

**Trastuzumab Resistance**

Amplification of ERBB2 (HER2) is associated with clinically aggressive breast tumors, shorter disease/recurrence-free survival, and poor overall survival (183). Trastuzumab is a recombinant humanized IgG1 monoclonal antibody that interacts with extracellular domain IV of ERBB2, inhibiting dimerization between ERBB2 and other EGFR family members (Figure 4F) (184). Although HER2+ BC responds quite well to trastuzumab (Herceptin™) therapy plus chemotherapy in the early stages of the disease, acquired resistance, however, to trastuzumab after 1–2 years of treatment is a frequent event following metastasis (185). Factors like HER2 degradation, overexpression of other RTKs, mutation of PI3KCA (PI3K catalytic subunit p110α), and loss of Phosphatase and Tensin Homolog Deleted on Chromosome 10 (PTEN) tumor-suppressive function have been linked with trastuzumab resistance (186). Continued application of trastuzumab in HER2+ cells with loss of PTEN encourages EMT and transforms HER2+ BC to TNBC (187). Strikingly, these transformed cells frequently exhibit mesenchymal features along with mesenchymal-specific gene expression profile, although the parental HER2+ cells show epithelial morphology with epithelial-specific gene signature. Since bCSCs exhibit chemoresistance to small-molecule targeted therapy, exploring the mechanism of trastuzumab resistance must have clinical implications. bCSCs confer drug resistance by activation of different prosurvival pathways, such as PI3K/AKT, NFκB, and JAK/STAT pathways (188). Thus, CD44+CD24-/low bCSC phenotype serves as a prognostic factor for clinical outcome and predictive factor for poor trastuzumab response in patients with HER2+ BC. Importantly, PI3K/AKT/mTOR activation has been implicated in both de novo and acquired trastuzumab resistance (189). Since PTEN loss and mutation of PI3KCA lead to aberrant downstream activation of PI3K/AKT/mTOR pathway, which in turn sustains bCSC population, both the factors correlate with trastuzumab resistance (190). Therefore, combining PI3K/AKT/mTOR inhibitors along with HER2 targeting drugs to overcome trastuzumab resistance provides an active area of research. Pan-class I PI3K inhibitors, such as buparlisib and pilaralisib when administered with trastuzumab (189), lapatinib (191), or trastuzumab and paclitaxel (192), are proven to be safer and successful in HER2+ advanced stage BC patients. IL-6-mediated bCSC expansion is another independent mechanism resulting in trastuzumab resistance (36). Moreover, STAT3 activation also stimulates breast cancer stem-like properties resulting in HER2 overexpression and trastuzumab resistance (193). Hence, targeting JAK/STAT pathway or administering IL-6 receptor-targeted antibody should overcome the trastuzumab resistance by reducing the bCSC burden. Additionally, CD47 blockade with trastuzumab also eliminates HER2+ BC cells, overcoming trastuzumab tolerance (194).

**Lapatinib Resistance**

Lapatinib is a reversible and selective receptor tyrosine kinase inhibitor, targeting both epidermal growth factor receptor (EGFR) and HER2 (195). In contrast to trastuzumab, lapatinib blocks kinases’ active ATP-binding site, thus interfering with receptor phosphorylation (Figure 4G). However, despite the initial response in HER2-overexpressing BC, acquired resistance to lapatinib turns out to be a frequent event in the course of treatment. Liu et al. have isolated and characterized several lapatinib-resistant HER2/ER+ BC clones from lapatinib-sensitive BT474 cells through chronic exposure to lapatinib. This group has identified that activation of AXL is associated with lapatinib resistance in these resistant BT474 clones (196). Evidence indicates a close association of breast CSCs in exerting lapatinib resistance. In this context, a recent study suggests that miR-205-5p is highly expressed in bCSCs. miR-205-5p represses ERBB/HER receptors in bCSCs, leading to resistance to targeted therapy (197). Silencing miR-205-5p in bCSCs, followed by lapatinib treatment, significantly reduces BC proliferation, resensitizing BC cells toward EGFR/anti-HER2 treatments. Furthermore, knockdown of miR-205-5p by locked oligonucleotides significantly reduces EMT and metastatic potential exerted by bCSCs (198). TGF-β-SMAD3 signaling also contributes to trastuzumab and lapatinib resistance, maintaining CSC phenotype in HER2+ settings (199). CD24 supports the expression of HER2 along with activation of PI3K/AKT signaling, resulting in lapatinib resistance (200). Hence, small-molecule inhibitors of SMAD3, or targeting CD24, can attenuate lapatinib resistance and increase the sensitivity of HER2+ BC cells to lapatinib.
BCSC-RELATED miRNA SIGNATURE MODULATING STEMNESS AND DRUG RESISTANCE

The regulation of BCSCs by miRNAs (~less than 25 nucleotides) is emerging as an innovative tool to deal with BCSC-driven drug resistance. Tumor suppressor miRNAs and OncomiRs have been implicated to play an essentially important role in the regulation of BCSC self-renewal, differentiation, tumor initiation, EMT, metastasis, and therapeutic resistance (3, 7, 201). In this section, we will briefly discuss these 2 types of BCSC-related microRNA signature, either suppressing or favoring drug resistance, through their regulation of multiple signaling networks.

Tumor Suppressor miRs in BCSCs

Several miRNAs, miR-30, miR-34, miR-200 family, miR-223, let-7, and miR-600 have been documented for tumor suppressive function (201). miR-223 is downregulated in CD44+/CD24−/low BCSC in TNBC compared with non-CSCs (202). Thus, overexpression of miR-223 sensitizes the TNBC cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis (202). miRNA expression profiling indicates that miR-200 family (miR-200a, miR-200b, miR-200c, miR-141, miR-429) is significantly downregulated in bCSCs (203). Overexpression of miR-200c inhibits clonogenicity and tumor-initiation potential of bCSCs, mainly through suppressing Notch signaling and its component JAG1 (201, 204). Similarly, miR-205 and miR-200 families are significantly downregulated in post-EMT metastatic BC, and thus overexpression of the miR200 family prevents TGF-β-induced EMT by negatively regulating both ZEB1 and ZEB2 (205). Let-7 miRNA, downregulated in bCSCs, is mainly engaged in restricting cell-cycle progression, self-renewal, and pluripotency of bCSCs by regulating factors like H-RAS, E2F2, and HMG-A2 (206). Let-7 miRNA can block self-renewal of bCSCs in ER+ BC background by targeting the Wnt/β-catenin pathway (207). Similarly, miR-30 negatively regulates the stemness of bCSCs and is significantly downregulated in bCSCs. Hence, overexpression of miR-30 diminishes aneikiss resistance and self-renewal potential of bCSCs by directly targeting integrin β3 and ubiquitin-conjugating enzyme 9 (208). Overexpression of miR-600 inhibits BCSC self-renewal and decreases in vivo tumorigenicity by inhibiting the Wnt/β-catenin pathway, as it targets the enzyme, SCD1, essential for producing active WNT proteins (209). Therefore, in absence of miR-600, the activated Wnt signaling promotes self-renewal, whereas overexpression of miR-600 induces BCSC differentiation into BC cells. Likewise, miR-34a restricts BCSC stemness and chemoresistance to doxorubicin via directly inhibiting the Notch signaling pathway. Notably, miR-34a is downregulated in bCSCs, and hence, overexpression of miR-34a inhibits the Notch signaling pathway, sensitizes bCSCs to paclitaxel, and inhibits BC proliferation, migration, and invasion (210). Similarly, miR-34c has reduced expression in breast CSCs, and overexpressing it significantly interferes with EMT, migration, and self-renewal properties through targeting Notch4 (211).

Oncogenic miRNAs (OncomiR) in BCSCs

Unlike tumor suppressor miRs, oncomiRs such as miR-21, miR-22, miR-155, miR-181, miR-9, and miR-221/222 cluster, show aberrant expression, and stimulate breast tumor growth, by suppressing apoptotic pathways, allowing proliferation, migration, invasion, and cell-cycle progression (3). Hence, strategies that target oncomiR can effectively block BCSC survival and function. miR-155 stimulates BCSC chemoresistance to doxorubicin by targeting CD44, CD90, and ABCG2, and inhibiting miR-155 resensitizes MDA-MB-231 BC cells to doxorubicin (212). Similarly, miR-181 also offers to be a promising therapeutic target to restrict bCSC function as it stimulates BCSC self-renewal potential and colony-formation properties (213). The miR-181/BRCA1 axis has been suggested to promote bCSC phenotypes in primary BC settings. Interestingly, a positive correlation is found between TGF-β expression level and miR-181/BRCA1 pathway activation in primary breast tumor samples (214). TGF-β pathway promotes BCSC population by inducing miR-181 at the posttranscriptional level and downregulating ATM kinase (215). An upregulated expression of miR-21 is positively correlated with poor prognosis, metastasis, and advanced stages of BC (216). miR-21 stimulates proliferation of BC cells and inhibition of apoptosis via suppressing tumor suppressors like PTEN, tropomyosin α1 (TPM1), and programmed cell death protein 4 (PDCD4) (7, 217, 218). Importantly, in BC cells, miR-21 regulates EMT through inhibition of PTEN function via p-AKT and p-ERK pathways, and re-expression of miR-21 leads to the acquisition of EMT phenotype in BCSCs with the activation of mesenchymal markers (vimentin, N-cadherin, α-SMA) (219, 220). Another important piece of evidence recognizes miR-22 as a crucial epigenetic modifier, regulating stemness, EMT, and metastasis in BC by silencing TET family-dependent chromatin remodeling (221). Importantly, two other oncomiRs, miR-9 and miR-221, are associated with poor clinical outcomes in BC patients. An enhanced expression of both miR-9 and miR-221 leads to an increase in the SP colonies with CSC-like features, and radically increasing BCSC stemness, migration, and invasion via upregulating Oct-4, Nanog, and CD133. However, knockdown of both miR-9 and miR-221 reduced the number of SP colonies and accordingly reduced BCSC self-renewal potency, migration, and invasion (222). Therefore, drugs targeting this class of drug-resistant oncomiRs can resensitize the BC cells to chemotherapies. Recently, MSC-released exosomes, containing specific miRNA sequences, are being utilized for the targeted killing of chemoresistant bCSCs (201, 223).

MECHANISMS AND APPROACHES TO OVERCOME MULTIMODAL DRUG RESISTANCE

In this section, we review the recent development of BCSC-targeting therapeutic platforms, based on small-molecule inhibitors, nanotherapeutics, molecules affecting different BC
signaling networks, and bCSC-specific immunotherapy for targeting breast cancer-associated multidrug resistance.

**ALDH1 Inhibitors, HIF1α Inhibitors, and EGFR/HER2 Inhibitors**

The previously established BCSC marker, ALDH, is a prerequisite for the maintenance of the drug-tolerant breast cancer stem-like population as it protects them from ROS-associated toxic effects (224). Since the ALDHhighCD44+ subpopulation reflects higher metastatic ability both in vitro and in vivo relative to ALDHlowCD44− and shows resistance to standard cancer therapies, inhibition of ALDH activity through all-trans retinoic acid (ATRA) or diethylaminobenzyldehyde (DEAB) sensitizes this population to treatment (51). ATRA reduces the activity of both ALDH1A1 and ALDH3A1 and stimulates CSC differentiation. Hence, combination therapy of ATRA with a standard chemotherapeutic agent such as paclitaxel and gemcitabine leads to survival and enrichment of bCSCs, which in turn depends on the HIFs. Studies involving mice breast tumor models further elaborated that chemotherapy along with HIF inhibitors, such as digoxin (interferes with HIF1α translation) or acrilavine (inhibits dimerization of HIF1α or HIF2α with HIF1β), might improve the survival of BC patients (225–227). Several HIF1 inhibitors including 2-methoxyestradiol, BAY 87-2243, and PX-478 2HCI are, therefore, undergoing clinical trials (228). Moreover, inhibition of the EGFR/HER2 signaling axis by lapatinib blocked the release of its intracellular domain (NICD), which then translocates to the nucleus and impacts gene expression in association with different transcription factors. Studies have established links between bCSCs, aberrant Notch signaling, and radio-/endocrine-/chemoresistance. A significantly higher expression of activated Notch1 is noted in the culture media of bCSCs, postradiation (66). A substantial induction of the JAG1 ligand is also evident on the surface of nonadherent bCSCs after fractionated radiation (232). Both JAG1 and Notch pathway contributes to chemoresistance in BC metastasizing to bone (236). Moreover, suppression of Notch1 signaling enhances antitumor efficacy of chemotherapy agents via reduction of bCSCs in TNBC (234). Notably, Notch ligand DLL1+ quiescent bCSCs drive chemoresistance via NFκB pathway in BC (235), and disease progression in ER+ BC is dependent on DLL1-mediated Notch1 signaling in bCSCs (236). Notch1 ligands, JAG1, and JAG2 are also overexpressed in endocrine-resistant luminal BC, resulting in an increased bCSC activity (237). Therefore, the blockade of Notch signaling is of clinical importance to eradicate resistant bCSCs and offer long-term disease-free survival.

**PI3K/AKT/mTOR Signaling**

PI3K is a family of lipid kinases that phosphorylate phosphatidylinositol (PI) at the intracellular membrane and plasma membranes. An increased PI3K/AKT/mTOR signaling in bCSCs has been documented over the years, contributing to survival, proliferation, metastasis, and drug resistance in BC cells (238, 239). Mutations, specifically in its catalytic domain, p110α, are the most frequent genetic events, affecting around one-third of BC patients. Alterations in the PI3K/AKT/mTOR pathway in bCSCs result in the TAM resistance in ER+ BC (240, 241). The interaction between PI3K and Wnt/β-catenin pathway is responsible for stemness and self-renewal abilities of bCSCs (242). Therefore, small-molecule inhibitors targeting the key players, PI3K, AKT, and mTOR can reverse the drug resistance and self-renewal abilities of breast cancer stem-like cells. Pan-PI3K inhibitors, such as buparlisib and pictilisib (inhibiting p110α/β/γ/δ); PI3K isoform-specific inhibitors such as alpelisib and taselisib (inhibiting p110α and p110α/γ/δ, respectively); AKT inhibitors such as ipatasertib, capivasertib (AZD5363), and veverisertib (MK-2206); PI3K/AKT dual inhibitor gedatolisib (PF-05212384); and mTOR inhibitors such as everolimus, vistusertib, and sapanisertib are currently available for the treatment of BC (243). B591, a novel PI3K inhibitor, has shown promising results in targeting breast CSCs in the mouse xenograft model, affecting both its self-renewal potential and EMT (244). However, despite substantial preclinical evidence, the innate and acquired resistance has limited the application of this group of inhibitors in BC.

**Notch Signaling**

Deregulated Notch signaling in bCSCs represents poor clinical outcomes in drug-resistant BC. Evolutionarily conserved Notch signaling is linked with cell differentiation and cell fate decisions. Notch signaling pathways include 4 receptors (Notch1–4) and 5 ligands such as delta-like ligand (DLL1), DLL3, DLL4, JAG1, and JAG2 (230, 231). Interaction with the Notch ligand leads to the release of its intracellular domain (NICD), which then translocates to the nucleus and impacts gene expression in association with different transcription factors. Studies have established links between bCSCs, aberrant Notch signaling, and radio-/endocrine-/chemoresistance. A significantly higher expression of activated Notch1 is noted in the culture media of bCSCs, postradiation (66). A substantial induction of the JAG1 ligand is also evident on the surface of nonadherent bCSCs after fractionated radiation (232). Both JAG1 and Notch pathway contributes to chemoresistance in BC metastasizing to bone (236). Moreover, suppression of Notch1 signaling enhances antitumor efficacy of chemotherapy agents via reduction of bCSCs in TNBC (234). Notably, Notch ligand DLL1+ quiescent bCSCs drive chemoresistance via NFκB pathway in BC (235), and disease progression in ER+ BC is dependent on DLL1-mediated Notch1 signaling in bCSCs (236). Notch1 ligands, JAG1, and JAG2 are also overexpressed in endocrine-resistant luminal BC, resulting in an increased bCSC activity (237). Therefore, the blockade of Notch signaling is of clinical importance to eradicate resistant bCSCs and offer long-term disease-free survival.

**Wnt/β-Catenin Signaling**

Wnt/β-catenin signaling contributes to self-renewal, migration, and invasion of bCSCs, leading to systematic dissemination in BC. A significantly higher level of Wnt/β-catenin signaling is noted in bCSCs compared with the bulk of the tumor (245). Hence, Wnt/β-catenin signaling serves as a novel target for restricting BC progression. A highly potent small-molecule inhibitor CWP232228 can preferentially inhibit bCSC proliferation via antagonizing the binding of β-catenin to T-cell factor (TCF) in the nucleus (246). Another natural product, gomisin M2, downregulates Wnt/β-catenin signaling and
inhibits bCSC proliferation, mammosphere formation, and self-renewal (247). Studies indicate multiple interaction points or crosstalk between Notch and Wnt/β-catenin signaling pathways, and thus it is essential to focus on Notch-Wnt synergies in BC progression (248). In a normal mammary setting, in response to Notch ligand DLL1, macrophages express Wnt ligands (Wnt3, Wnt10A, and Wnt16), important for mammary stem cell numbers and activity (249). Thus, the proteins exerting regulatory effects on both these pathways should serve as a novel therapeutic target and targeted in BC. GSK3β is one such protein that regulates β-catenin stability as well as phosphorylates Notch ICD (250).

Hedgehog Signaling
The Hh signaling is another novel target in BC since it is frequently upregulated in bCSCs and contributes to CSC self-renewal and stemness maintenance. The cancer-associated fibroblasts (CAFs) within TME support the maintenance of CSC function in breast tumors via their regulation of both Wnt/β-catenin and Hh signaling. Briefly, CAFs promote BC progression through proliferation, invasion, matrix remodeling (via matrix production and crosslinking, matrix stiffness, force-mediated matrix remodeling), macrophage, and endothelial cell crosstalk (via secretion of VEGF, exosomes, HGF production), chemoresistance, and immunosuppression (251–253). Notably, BC shows divergent CAF phenotypes, including FAP-positive (fibroblast-activating protein α1) CAFs driving immunosuppression and resistance to PD-L1 therapy (254). According to Friedman et al., two distinct subpopulations of CAFs (S100A4+ and PDPN+) exist in human breast tumors, where their ratio decides the clinical outcomes across subtypes and is highly correlated with BRCA mutations in TNBC (255). The interaction between the breast cancer cell and fibroblasts also induces the CAF phenotype through activation of Notch signaling (256). Hence, understanding the full repertoire of CAFs and the dynamic changes as breast tumors evolve can improve the precision of treatment and reverse drug resistance. BSCCs secrete the Hedgehog ligand, SHH, which controls CAFs through activation of Hh signaling (257). The CAFs, in turn, secrete some factors that result in the expansion and self-renewal of bCSCs. Therapeutic targeting of CAFs using the inhibitor molecule of Smoothened, the main effector molecule of the Hh pathway, sensitizes TNBC xenograft models to docetaxel (258). Tetraspanin 8 (TSPAN8), a membrane glycoprotein, enhances BC stemness by activating Hh signaling (259). Tetraspanin 8 (TSPAN8), a membrane glycoprotein, enhances BC stemness by activating SHH signaling (259). Activation of Hh signaling results in salinomycin resistance in tumor spheres, generated from the MCF-7 cell line (260). However, the inhibition of the Hh pathway by cyclopamine can sensitize the MCF-7 cells to paclitaxel. Therefore, exploring the detailed mechanisms of Hh-driven bCSC signaling can help in the designing of novel drug candidates to reverse BC drug resistance.

Targeting bCSC Metabolism
Maintenance of a reduced level of ROS through metabolic reprogramming is one of the strategies adopted by bCSCs to avoid oxidative stress, which is attributed to the higher expression of ROS scavengers including glutathione peroxidase, superoxide dismutase, and catalase. There is a close association between ROS levels and bCSC-driven radioresistance. Pharmacological inhibition of ROS scavengers in bCSCs distinctly reduces their clonogenicity potential, resulting in radioresititization (261). Moreover, ROS generating drugs can target drug-resistant bCSCs through induction of premature senescence (262). To mitigate a higher energy demand of fast-growing tumor cells, bCSCs further reshape their metabolic machinery. BSCCs are metabolically plastic, which allows them to dynamically switch their metabolic state to favor glycolysis or oxidative phosphorylation (OXPHOS). Unlike the non-CSCs that majorly depend on glycolysis, bSCCs can favor either glycolysis or OXPHOS, depending on the niche. The glycolytic switch in SCs, in general, contributes to stemness. Metabolic switching from OXPHOS to glycolytic phenotype, known as the Warburg effect, is another survival adaptation exhibited by bSCCs, to sustain growth in nutrient-deprived or hypoxic environments (263–265). Since BCL-2 protein is a crucial regulator of mitochondrial respiration, inhibition of BCL-2 prevents OXPHOS (266). This, in turn, reduces the bCSC burden that depends on OXPHOS. Several OXPHOS-targeting compounds, such as atovaquone, arsenic trioxide, and phenformin are undergoing clinical trials for different solid tumors (267, 268). Interestingly, CSCs with metastatic potential follows a distinct metabolic signature. According to Luo et al., metabolic or oxidative stress plays a crucial role concerning bCSCs’ plasticity between quiescent mesenchymal-like (M) state and proliferative epithelial-like (E) state. Oxidative stress produced due to H$_2$O$_2$, 2DG, and hypoxia regulates the transition from ROSlow M-bCSCs into ROShigh E-bCSCs (269). Importantly, hexokinase 2, which catalyzes the initial step of glucose metabolism, is a major target of metformin for altering bCSC metabolism. Therefore, exploiting the metabolic switching of bSCCs could essentially provide a novel platform targeting the multidrug-resistant bCSC population.

Nanotherapeutics Against bSCCs
Nanoparticle-based drug carriers (nanocarriers) are often used to specifically deliver chemotherapeutic drugs, siRNAs, miRNAs, and antibodies, designed based on identifying antibodies/aptamers against bCSC-specific markers (Figure 5A) (270, 271). Due to the site-specific delivery and improved stability and bioavailability, nanocarriers are appearing as novel platforms for targeting (1) bCSC-specific antigens such as CD44 and ALDH1, (2) drug-efflux ABC transporters (ABCB1 and ABCG2), (3) self-renewing signaling pathways, (4) autophagy process, (5) metabolism, and (6) TME. Sahli et al. developed a triple-drug delivery platform, composed of paclitaxel, verteporfin, and combretastatin (CA4) inside polymer-lipid hybrid nanoparticles to target bCSCs and associated tumor vasculature (272). Gao et al. have further improvised these smart platforms to simultaneously target bSCCs and bulk breast tumor cells by encapsulating the combination of bCSC-specific inhibitor with a chemotherapeutic agent, along with a phytochemical agent or RNA-based therapy (273). HA-modified mesoporous silica nanoparticles loaded with 8-hydroxyquinoline consisting of docetaxel have been designed to eliminate bSCCs (274). This HA modification enables an enhanced uptake of nanoparticles by bSCCs. Another novel
chitosan-decorated doxorubicin-encapsulated nanocarrier has been developed to target CD44 surface receptors of bCSCs (275). Recently, a nanocarrier system using PEG-PLA copolymers has been designed for the delivery of autophagy inhibitor molecule, chloroquine, in complex with doxorubicin and docetaxel to eliminate both bCSCs and non-bCSCs (276). Since bCSCs require a specialized niche to survive, nanoparticle-based platforms targeting ECM modifying enzyme lysyl oxidase result in TME disruption (277). A novel HA-based platform encapsulating CD44-targeted docetaxel conjugate is another example of nanocarrier, killing both bCSCs and non-bCSCs (278).

**bCSC-Targeting Strategy Focusing on Immunotherapy**

Since CSCs exhibit distinct immune characteristics and express specific immune markers, targeting those molecules as a part of immunotherapy is employed to target CSCs. Different strategies like DC vaccine, adaptive T-cell transfer, oncolytic virus, ICIIs, and combination therapies are recent approaches to target bCSCs.

**DC-Based Vaccine**

DCs loaded with CSC lysate or mRNA, administered as vaccines, are capable of eliciting cancer-specific immune responses (279). Notably, DCs are the professional antigen-presenting cells (APCs) that process the antigenic material and present peptide antigens to T cells and activate them. Interestingly, DCs in BC patients exhibit decreased antigen uptake, reduced antigen processing, reduced expression of costimulators, weak migration profile, along decreased IL-12 production (280, 281). Patients with advanced breast and ovarian cancers can be successfully vaccinated by DC loaded with HER2/Neu- or MUC1-derived antigenic peptides (282). Phase-I clinical trial with metastatic BC showed that fusion of breast tumor cells with DCs resulted in immunological and clinical antitumor responses (283). DC pulsed with breast tumor lysate has proved to be a standard method for a source of BC antigen, capable of eliciting anticancer immune responses (284). BCSC-RNA-pulsed DC vaccine also effectively kills breast tumor cells through activation of CD4+ T_h lymphocytes and CD8+ cytotoxic T cells. This study highlights the efficacy of bCSC-RNA for priming DC cells in evoking immune response against drug-resistant CSC populations. However, DC-based vaccines present a few drawbacks; they are both cost-effective and time-consuming for patient-specific treatment. Factors like antigenic peptide or CSC-RNA loading on DC, route of administration, and doses are yet to be standardized to resolve these technical limitations.
Adaptive T-Cell Therapy

Adaptive T-cell therapy is a personalized mode of immunotherapy to target CSCs. Here, tumor immune lymphocytes (TILs) with intrinsic antitumor activity are isolated from cancer-bearing patients. Following isolation, TILs are cultured in the presence of IL-2 so that they can recognize tumor-associated antigens on cancer cells, and eventually release cytotoxic cytokines, perforin, and granzymes (285). The recent approach focuses on designing CAR-T cells against the CSC surface antigens in different cancer models to achieve complete regression of tumor (286). CARs generally constitute the extracellular binding domain, a single-chain variable fragment (scFv) specific for a tumor antigen, an extracellular spacer domain, a transmembrane domain, followed by an intracellular signaling domain (Figure 5D). EGFR-specific CAR-T cells have shown promising results in high EGFR-expressing TNBC cell lines and patient-derived xenograft mouse models (287). Another recent report highlights promising results for HER2-specific second-generation CAR-T therapy for the treatment of breast-to-brain metastasis (288). Other bCSC markers targeted by CAR-T therapy include c-Met, CD133, CD166, CD47, EpCAM, and LGR5 (55, 289, 290). Despite the remarkable clinical success of CAR-T therapy in hematologic cancers, its application is limited in solid tumors. Due to the lack of chemokine expression required for the infiltration of CAR-T cells into the tumor tissues and dense fibrotic matrix in solid tumors, the ability of CAR to get recruited at the tumor site and infiltrate is considerably affected (291). Frequently, CAR-T cells fail to penetrate the tumor tissues through the vascular endothelium (292). Therefore, instead of systemic administration, regional administration of CAR-T cells in solid cancers will be more effective. Altogether, the major limitation of this approach includes burdensome and expensive preparation to isolate the patient-derived T cells and the major side effects resulting from cytokine release syndrome.

Oncolytic Viral Therapy

Oncolytic viruses (OVs), a novel class of DNA/RNA-attenuated viruses that selectively infect, replicate inside the tumor cells, and eventually kill them either through modulating the TME or via antitumor response (Figure 5C) (293). These naturally occurring or genetically engineered viruses have the potential to convert an “immunologically cold” TME into an “immunologically hot” one by increasing the net influx of TILs, consisting of CD4+ and CD8 + T cells, B cells, and NK cells (293, 294). Activated CD8+ cytotoxic T cells and NK cells are associated with a good prognosis, whereas the presence of Foxp3+ Treg cells within the breast TME is associated with a poor prognosis, due to their role in immunosuppression. Immunologically “cold” tumors exhibit a low mutational burden, poor MHC presentation of tumor antigen, poor migration of TILs, and also have reduced expression of PD-L1 on the surface of tumor cells, thus making the response to ICIs inadequate (295). Interestingly, OVs induce a strong antiviral tumor immune response through the production of cytokines like type-1 interferon that in turn promotes PD-L1 expression on tumor cells and also cytokines, such as CCL3 and CCL4, attracting PD-1+ or CTLA-4+ immune cells within TME (296). Eriksson et al. indicated that OVs, Ad5/3-Delta24 and Ad5.pk7-Delta 24, can selectively kill CD44+ CD24+/low bCSC population. Oncolytic herpes simplex virus, oHSV G47Δ, effectively kills bCSCs both in vitro and in vivo, derived from SK-BR-3 and primary human BC cells (297). A randomized phase II study by Bernstein et al. reported that the combination of oncolytic reovirus (pelareorep) with paclitaxel significantly increased survival of metastatic BC patients (298). Combining pelareorep with paclitaxel, along with anti-PD-L1 antibody, avelumab (NCT04215146) is presently undergoing phase II clinical study in BC patients (299).

Immune Checkpoint Inhibitors

Immune checkpoint ligands such as PD-L1 and PD-L2 are highly expressed on CSCs. The immune cells, on the other hand, express the receptor for these ligands, PD-1. Now, the interaction between PD-1 and PD-L1/PD-L2 interferes with T-cell proliferation and activity, leading to tumor immune suppression, thus serving as a strategy to immune escaping of CSCs (300). Therefore, immune checkpoint blockade of PD-L1/PD-L2 is emerging as a novel therapeutic approach, whereby these CSC-specific ligands are engaged by ICIs, thus making it possible to target CSCs for programmed cell death. Notably, multiple clinical trials on ICIs, targeting CTLA-4, PD-1, and PD-L1 are in progress that are either administered as a single agent or in combination with trastuzumab or with chemotherapeutic drugs, in HER2-enriched and TNBC settings, respectively. In March 2019, FDA has approved the clinical application of anti-PD-L1 antibody, atezolizumab, in combination with nab-paclitaxel, to be administered as the first-line therapy to metastatic or locally advanced PD-L1+ TNBC patients (301). A recent phase Ib clinical study by Nanda et al. explored the antitumor efficacy and safety profile of PD-1 inhibitor molecule pembrolizumab in advanced TNBC patients (302). Furthermore, certain drugs that stimulate PD-L1 degradation can be administered as a combination therapy with ICIs to significantly enhance the efficacy of cancer immunotherapy (303).

CONCLUSION AND PERSPECTIVES

Despite ongoing efforts using novel chemotherapeutics, ICIs, small-molecule inhibitors, or combinations of these innovative therapeutic platforms, bCSC-driven drug resistance remains a public health concern globally. Exploring better bCSC-targeting substitutes is thus the way forward. Radionuclides conjugated with monoclonal antibodies (mAb), administered in radioimmunotherapy (RIT), involve highly potent α- or β-particles to deliver cytotoxic radiation to cancer cells or TME (Figure 5B) (304). 212Pb-TCMC-trastuzumab using lead-212 (α-particle emitter), is undergoing phase I clinical trial to study its antitumor effects in HER2+ intraperitoneal cancer patients (305, 306). Another isotope, 111In-NLS-trastuzumab, is being administered to kill trastuzumab-resistant BC cell lines via the emission of Auger electrons (307). Recently, radionuclide therapy using 223Ra (α-particle emitter) has been successful in delaying the growth of DTCs in early-stage BC (308). Radioactive
iodine therapy with single-domain antibodies targeting HER2 (131I-GMIB-anti-HER2-VHH1) documents the first-in-human study, demonstrating the safety profile and efficacy of radionuclide in the treatment of HER2+ BC (309). Importantly, RIT is advantageous in the management of MRD, residual tumor margins following surgery, and CTCs in hematologic malignancy, compared with external beam radiation therapy. Likewise, nanobiotechnology should be fully explored to precisely target bCSC-specific novel antigens, to eliminate the same. The efficacy of synthetic nanoparticles, such as silver (AgNPs) (310), gold (AuNPs) (311), and selenium (SeNPs) (312), has been studied extensively in different types of solid cancers. Notably, AgNPs (313) and AuNPs (314) both have shown encouraging results in BC, although the potency of the same in target killing of breast CSCs is not known. Hence, the potential of this family of radionuclides and nanoparticles should be considered in the targeted killing of bCSCs. In conclusion, cotargeting of multiple signaling networks contributing to bCSC survival and proliferation, by virtue of multimodal targeted therapeutics, will lay the foundation to overcome BC drug resistance.

AUTHOR CONTRIBUTIONS

TS has written the manuscript and prepared the figures and table for the manuscript. KEL has edited the manuscript and provided valuable suggestions and inputs in modifying the manuscript. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clin (2021) 71:269–49. doi: 10.3322/caac.21660
2. Abad E, Graifer D, Lyakhovich A. DNA Damage Response and Resistance of Cancer Stem Cells. Cancer Lett (2020) 474:106–17. doi: 10.1016/j.canlet.2020.01.008
3. Niu T, Zhang W, Xiao W. MicroRNA Regulation of Cancer Stem Cells in States of Quiescence, Proliferation or Differentiation: Use of Gel Stress in Combination With Stem Cell Growth Factors. Oncol Lett (2016) 12:355–60. doi: 10.3892/ol.2016.4757
4. Quaglino E, Conti L, Cavallo F. Breast Cancer Stem Cell Antigens as Targets for Immunotherapy. Semin Immunol (2020) 47:101386. doi: 10.1016/j.smim.2020.101386
5. Dees S, Ganesan R, Singh S, Grewal IS. Emerging CAR-T Cell Therapy for the Treatment of Triple-Negative Breast Cancer. Mol Cancer Ther (2020) 19:2409–21. doi: 10.1158/1535-7163.MCT-20-0385
6. Zhao Y, Alakhova DY, Kabanov AV. Can Nanomedicines Kill Cancer Stem Cells? Adv Drug Deliv Rev (2013) 65:763–83. doi: 10.1016/j.addr.2013.09.016
7. Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, et al. Breast Cancer. Nat Rev Dis Primers (2021) 7:64. doi: 10.1038/s41572-019-0111-2
8. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene Expression Patterns of Breast Carcinomas Distinguish Tumor Subclasses With Clinical Implications. Proc Natl Acad Sci (2001) 98:10869–74. doi: 10.1073/pnas.191367098
9. Lukong KE. Understanding Breast Cancer – The Long and Winding Road. BBA Clin (2017) 7:64–77. doi: 10.1016/j.bbacli.2017.01.001
10. Kumar P, Aggarwal R. An Overview of Triple-Negative Breast Cancer. Arch Gynecol Obstet (2016) 293:247–69. doi: 10.1007/s00404-015-3859-y
11. Prat A, Pineda E, Adamo B, Galván P, Fernández A, Gaba L, et al. Clinical Implications of the Intrinsic Molecular Subtypes of Breast Cancer. Breast (2015) 24 Suppl 2:S26–35. doi: 10.1016/j.breast.2015.07.008
12. Foulkes WD, Smith IE, Reis-Filho JS. Triple-Negative Breast Cancer. N Engl J Med (2010) 363:1938–48. doi: 10.1056/NEJMoa1001389
13. Brasso-Maristany F, Griguolo G, Pascual T, Paré L, Nuciforo P, Lombard-Cussac A, et al. Phenotypic Changes of HER2-Positive Breast Cancer During and After Dual HER2 Blockade. Nat Commun (2020) 11:385. doi: 10.1038/s41467-019-14111-3
14. METABRIC Group, Curtis C, Shah SP, Chin S-F, Tsuruhashi G, Rueda OM, et al. The Genomic and Transcriptomic Architecture of 2,000 Breast Tumours Reveals Novel Subgroups. Nature (2012) 486:346–52. doi: 10.1038/nature10983
15. Russnes HG, Lingjærde OC, Børresen-Dale A-L, Caldas C. Breast Cancer Molecular Stratification. Am J Pathol (2017) 187:2152–62. doi: 10.1016/j.ajpath.2017.04.022
16. Turner KM, Yeo SK, Holm TM, Szaughnessy E, Guan J-L. Heterogeneity Within Molecular Subtypes of Breast Cancer. Am J Physiol Cell Physiol (2021) 321:C343–54. doi: 10.1152/ajpcell.00109.2021
17. Russano M, Napolitano A, Ribelli G, Iuliani M, Simonetti S, Citarella F, et al. Liquid Biopsy and Tumor Heterogeneity in Metastatic Solid Tumors: The Potentiality of Blood Samples. J Exp Clin Cancer Res (2020) 39:95. doi: 10.1186/s13046-020-01601-2
18. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing. N Engl J Med (2012) 366:883–92. doi: 10.1056/NEJMoa113205
19. Almirzaie S, Bagherzadeh M, Akhbari MR. Liquid Biopsy in Breast Cancer: A Comprehensive Review. Clin Genet (2019) 95:643–60. doi: 10.1111/cge.13514
20. Alba-Bernal A, Lavado-Velazuela R, Dominguez-Recio ME, Jiménez-Rodriguez B, Queipo-Ortuño MI, Alba E, et al. Challenges and Achievements of Liquid Biopsy Technologies Employed in Early Breast Cancer. ElBioMedicine (2020) 62:103100. doi: 10.1016/j.ebiomed.2020.103100
21. Kingston B, Curtis RJ, Bye H, Beaney M, Walsh-Crestani G, Hrebien S, et al. Genomic Profile of Advanced Breast Cancer in Circulating Tumour DNA. Nat Commun (2021) 12:2423. doi: 10.1038/s41467-021-22605-2
22. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating Mutant DNA to Assess Tumor Dynamics. Nat Med (2008) 14:985–90. doi: 10.1038/nm.1789
23. Yuan T, Huang X, Woodcock M, Du M, Dittmar R, Wang Y, et al. Plasma Circulating Mutant DNA to Assess Tumor Dynamics. Nat Med (2010) 16:985–9. doi: 10.1038/nm.1789
24. Alba-Bernal A, Lavado-Velazuela R, Dominguez-Recio ME, Jiménez-Rodriguez B, Queipo-Ortuño MI, Alba E, et al. Challenges and Achievements of Liquid Biopsy Technologies Employed in Early Breast Cancer. ElBioMedicine (2020) 62:103100. doi: 10.1016/j.ebiomed.2020.103100
25. Kingston B, Curtis RJ, Bye H, Beaney M, Walsh-Crestani G, Hrebien S, et al. Genomic Profile of Advanced Breast Cancer in Circulating Tumour DNA. Nat Commun (2021) 12:2423. doi: 10.1038/s41467-021-22605-2
26. Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating Mutant DNA to Assess Tumor Dynamics. Nat Med (2008) 14:985–90. doi: 10.1038/nm.1789
27. Yuan T, Huang X, Woodcock M, Du M, Dittmar R, Wang Y, et al. Plasma Circulating Mutant DNA to Assess Tumor Dynamics. Nat Med (2010) 16:985–9. doi: 10.1038/nm.1789
28. Desmedt C, Voet T, Sotiriou C, Campbell PJ. Next-Generation Sequencing in Breast Cancer: First Take Home Messages. Curr Opin Oncol (2012) 24:595–604. doi: 10.1097/CCO.0b013e328359554e
29. Roy-Chowdhuri S, de Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, Broaddus R, et al. Multigene Clinical Mutational Profiling of Breast Carcinoma Using Next-Generation Sequencing. Am J Clin Pathol (2015) 144:713–21. doi: 10.1093/ajcpqjcy929Q
Endocrine Resistance in Metastatic Breast Cancer. Nat Commun (2016) 7:10442. doi: 10.1038/ncomms10442
30. Meyer MJ, Fleming JM, Lin AF, Hussein SA, Ginsburg E, Vanderhaak BK. CD44posCD90hiCD133+Breast Defines Xenograft-Initiating Cells in Estrogen Receptor-Negative Breast Cancer. Cancer Res (2010) 70:4624–33. doi: 10.1158/0008-5472.CAN-09-3619
31. Gilcier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, et al. ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome. Cell Stem Cell (2007) 1:555–67. doi: 10.1016/j.stem.2007.08.014
32. Croker AK, Allan AL. Inhibition of Aldehyde Dehydrogenase (ALDH) Activity Reduces Chemotherapy and Radiation Resistance of Stem-Like ALDH+CD44+ Human Breast Cancer Cells. Breast Cancer Res Treat (2012) 133:75–87. doi: 10.1007/s10549-011-1692-y
33. Sarmiento-Castro A, Caamaño-Gutiérrez E, Sims AH, Hull NJ, James MI, Santiago-Gómez A, et al. Increased Expression of Interleukin-1 Receptor Characterizes Anti-Estrogen-Resistant ALDH+ Breast Cancer Stem Cells. Stem Cell Rep (2020) 15:307–16. doi:10.1016/j.stemcr.2020.06.020
34. Munz M, Baueerle PA, Gires O. The Emerging Role of EpCAM in Cancer Stem Cells. Cancer Res (2009) 69:5627–9. doi: 10.1158/0008-5472.CAN-09-0654
35. Mal A, Bukhari AB, Singh RK, Kapoor A, Barai A, Deshpande I, et al. EpCAM-Mediated Cellular Plasticity Promotes Radiation Resistance and Multiple Metastasis in Breast Cancer. Front Cell Dev Biol (2021) 9:659763. doi: 10.3389/fcell.2020.597673
36. Baccelli I, Schneeweiss A, Riethdorf S, Stenzinger A, Schillert A, Vogel V, et al. Identification of a Population of Blood Circulating Tumor Cells From Breast Cancer Patients That Initiates Metastasis in a Xenograft Assay. Nat Biotechnol (2013) 31:539–44. doi: 10.1038/nbt.2576
37. Wang T, Gantier MP, Xiang D, Bean AG, Bruce M, Zhou S-F, et al. EpCAM Aptamer-Mediated Survivin Sensitizing Cancer Stem Cells to Doxorubicin in a Breast Cancer Model. Theranostics (2015) 5:1456–72. doi: 10.7150/thno.11669
38. Chaffer CL, Weinberg RA. A Perspective on Cancer Cell Metastasis. Science (2011) 331:1559–64. doi: 10.1126/science.1203543
39. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of Chemokine Receptors in Breast Cancer Metastasis. Nature (2001) 410:50–6. doi: 10.1038/35065016
40. Liang Z, Yoon Y, Votav O, Johnson GM, Williams L, Shim H. Silencing of CXCR4 Blocks Breast Cancer Metastasis. Cancer Res (2005) 65:967–71. doi: 10.1158/0008-5472.CAN-04-3175
41. Chatterjee S, Behnam Azad B, Nimmagadda S. The Intricate Role of CXCR4 in Cancer. Adv Cancer Res (2014) 124:31–82. doi: 10.1016/B978-0-12-400012-7.00012-1
42. Chen IX, Chauhan VP, Posada J, Ng MR, Wu MW, Adstamongkonkul P, et al. Blocking CXCR4 Alleviates Desmolipase, Increases T-Lymphocyte Infiltration, and Improves Immunotherapy in Metastatic Breast Cancer. Proc Natl Acad Sci USA (2019) 116:4558–66. doi: 10.1073/pnas.1815511156
43. Yi T, Zhai B, Yu Y, Kiyotsugu Y, Raschle T, Etkorn M, et al. Quantitative phosphoproteomics Analysis Reveals System-Wide Signaling Pathways Downstream of SDF-1/CXCR4 in Breast Cancer Stem Cells. Proc Natl Acad Sci (2014) 111:E2182–90. doi: 10.1073/pnas.140493111
44. Chaffer CL, Brueckmann I, Schell C, Kaestli AJ, Wiggins PA, Rodrigues LO, et al. Normal and Neoplastic Nonstem Cells can Spontaneously Convert to a Stem-Like State. Proc Natl Acad Sci (2011) 108:7990–5. doi: 10.1073/pnas.1012451108
45. Gupta PB, Chaffer CL, Weinberg RA. Cancer Stem Cells: Mirage or Reality? Nat Med (2009) 15:1010–2. doi: 10.1038/nm0909-1010
46. Reid PA, Wilson P, Li Y, Marcu LG, Bezak E. Current Understanding of Cancer Stem Cells: Review of Their Radiobiology and Role in Head and Neck Cancers. Head Neck (2017) 39:1920–32. doi: 10.1002/hed.24848
47. Phillips TM, McBride WH, Jain N, Pajonk F. The Response of CD24(-)/CD44+ Breast Cancer Cells to Radiation. J Natl Cancer Inst (2006) 98:1777–85. doi: 10.1093/jnci/dji495
48. Lagadec C, Vlahi E, Della Donna L, Delmeezian C, Pajonk F. Radiation-Induced Reprogramming of Breast Cancer Cells. Stem Cells (2012) 30:833–44. doi: 10.1002/stem.1058
49. Lee SY, Jeong EK, JU MK, Jeon HM, Kim MY, Kim CH, et al. Induction of Metastasis, Cancer Stem Cell Phenotype, and Oncogenic Metabolism in
Cancer Cells by Ionizing Radiation. *Mol Cancer* (2017) 16:10. doi: 10.1186/s12943-016-0577-z

69. Deniz Sun, Midik R, Moliteri A, Zambetti M, Hrushesky WJM, Retky MW, et al. Breast Cancer Recurrence Dynamics Following Adjuvant CMF Is Consistent With Tumor Dormancy and Mastectomy-Driven Acceleration of the Metastatic Process. *Ann Oncol* (2005) 16:1449–57. doi: 10.1093/annonc/mdi280

70. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu M-F, et al. Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy. *J Natl Cancer Inst* (2008) 100:672–9. doi: 10.1093/jnci/djn123

71. Basu S, Dong Y, Kumar R, Jeter C, Yang DG. Slow-Cycling (Dormant) Cancer Cells in Therapy Resistance, Cancer Relapse and Metastasis. *Semin Cancer Biol* (2021) 78:90–103. doi: 10.1016/j.semcancer.2021.04.021

72. Park S-Y, Nam J-S. The Force Awakens: Metastatic Dormant Cancer Cells. *Exp Mol Med* (2020) 52:569–81. doi: 10.1038/s12276-020-0423-z

73. Banys M, Hartkopf AD, Krawczyk N, Kaiser T, Meier-Stiegen F, Fehm T, et al. Dormancy in Breast Cancer. *Breast Cancer (Dove Med Press)* (2012) 2:418–91. doi: 10.2147/BCTT.S26431

74. Korentzelos D, Clark AM, Wells A. A Perspective on Therapeutic Pan-Targeting of Cancer Cells. *Int J Oncol* (2019) 54:111–22. doi: 10.3892/ijon.2019.10379

75. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LMG, Pe’er J, et al. Vascular Channel Formation by Human Melanoma Cells In Vivo and In Vitro: Vasculogenic Mimicry. *Am J Pathol* (1999) 155:739–52. doi: 10.1016/S0002-9440(10)65173-5

76. Shirakawa K, Wakasugi H, Heike Y, Watanabe I, Yamada S, Saito K, et al. Expression of Twist1 in Hepatocellular Carcinoma: Its Role in Vascularization and Neoplastic Cell Migration. *Int J Oncol* (2010) 36:865–72. doi: 10.3892/ijon.2010.1037

77. Liu TJ, Sun BC, Zhao XL, Zhao XM, Sun T, Gu Q, et al. CD133+ Cells With Vasculogenic Mimicry. *Hepatology* (2017) 66:2272, 2272e.1. doi: 10.1002/hup.10423

78. Hangauer MJ, Viswanathan VS, Ryan MJ, Bole D, Eaton JK, Matov A, et al. Targeting Ferroptosis in Vascular Channel Formation by Human Melanoma Cells. *Exp Biol Med* (2021) 246:1564–75. doi: 10.1177/1044579X2100122X

79. Park S-Y, Nam J-S. The Force Awakens: Metastatic Dormant Cancer Cells. *Exp Mol Med* (2020) 52:569–81. doi: 10.1038/s12276-020-0423-z

80. Banys M, Hartkopf AD, Krawczyk N, Kaiser T, Meier-Stiegen F, Fehm T, et al. Dormancy in Breast Cancer. *Breast Cancer (Dove Med Press)* (2012) 2:418–91. doi: 10.2147/BCTT.S26431

81. Nazir F, Bordi M, Cianfanelli V, Locatelli F, Cecconi F. Autophagy and Cancer Stem Cells: Molecular Mechanisms and Therapeutic Applications. *Cell Death Differ* (2019) 26:690–702. doi: 10.1038/s41418-019-0292-y

82. Gong C, Song E, Codogno P, Mehrpour M. The Roles of BECN1 and Autophagy in Cancer Are Context Dependent. *Autophagy* (2012) 8:1853–5. doi: 10.4161/auto.21996

83. Wolf J, Dewi DL, Fredebohm J, Müller-Decker K, Flechtenmacher C, Hoheisel JD, et al. A Mammosphere Formation RNAi Screen Reveals That ATG14 Promotes a Breast Cancer Stem-Like Phenotype. *Breast Cancer Res* (2013) 15:R109. doi: 10.1186/bcr3576

84. Chatterjee M, van Golen KL. Breast Cancer Stem Cells Survive: Periods of Farnesyl-Transferase Inhibitor-Induced Dormancy by Undergoing Autophagy. *Bone Marrow Res* (2011) 2011:1–7. doi: 10.1155/2011/362938

85. Han Y, Fan S, Qin T, Yang J, Sun Y, Lu Y, et al. Role of Autophagy in Breast Cancer and Breast Cancer Stem Cells (Review). *Int J Oncol* (2018) 52:1057–72. doi: 10.3892/ijo.2018.4270

86. Gong C, Bauxy C, Tonelli G, Yue W, Deloménie C, Nicolas V, et al. Beclin 1 and Autophagy Are Required for the Tumorigenicity of Breast Cancer Stem-Like/Progenitor Cells. *Oncogene* (2013) 32:2261–2272, 2272e.1–11. doi: 10.1038/onc.2012.232

87. Han Q, Deng Y, Chen S, Chen R, Yang M, Zhang Z, et al. Downregulation of ATG5-Dependent Macropathoautophagy by Chaperone-Mediated Autophagy Promotes Breast Cancer Cell Metastasis. *Sci Rep* (2017) 7:4759. doi: 10.1038/s41598-017-04994-x

88. Wang M, Zhang J, Huang Y, S, Shao G, Feng S, et al. Cancer-Associated Fibroblasts Autophagy Enhances Progression of Triple-Negative Breast Cancer Cells. *Med Sci Monit* (2019) 25:9384–40. doi: 10.12659/msm.920280

89. Yue W, Hamai T, Tonelli G, Bauxy C, Nicolas V, Tharinger H, et al. Inhibition of the Autophagic Flux by Salinomycin in Breast Cancer Stem-Cells Promotes Breast Cancer Stem-Like/Progenitor Cells Interferes With Their Maintenance. *Autophagy* (2013) 9:714–9. doi: 10.4161/auto.23997

90. Fletcher JL, Haber M, Henderson MJ, Norris MD. ABC Transporters in Cancer: More Than Just Drug Efflux Pumps. *Nat Rev Cancer* (2010) 10:147–56. doi: 10.1038/nrc2789

91. Lou H, Dean M. Targeted Therapy for Cancer Stem Cells: The Patched Side Population. *Int J Oncol* (2018) 52:1057–72. doi: 10.3892/ijo.2018.4270

92. Patel M, Giudice AM, Scotlandi K. The ABC Subfamily A Transporters: The BCRP Like/Progenitor Cells Interferes With Their Maintenance. *Autophagy* (2013) 9:714–9. doi: 10.4161/auto.23997

93. Pasello M, Giudice AM, Scotlandi K. The ABC Subfamily A Transporters: The BCRP Like/Progenitor Cells Interferes With Their Maintenance. *Autophagy* (2013) 9:714–9. doi: 10.4161/auto.23997

94. Pasello M, Giudice AM, Scotlandi K. The ABC Subfamily A Transporters: The BCRP Like/Progenitor Cells Interferes With Their Maintenance. *Autophagy* (2013) 9:714–9. doi: 10.4161/auto.23997

95. Pasello M, Giudice AM, Scotlandi K. The ABC Subfamily A Transporters: The BCRP Like/Progenitor Cells Interferes With Their Maintenance. *Autophagy* (2013) 9:714–9. doi: 10.4161/auto.23997

96. Pasello M, Giudice AM, Scotlandi K. The ABC Subfamily A Transporters: The BCRP Like/Progenitor Cells Interferes With Their Maintenance. *Autophagy* (2013) 9:714–9. doi: 10.4161/auto.23997
108. Sun M, Yang C, Zheng J, Wang M, Chen M, Le DQS, et al. Enhanced efficacy of chemotherapy for Breast Cancer Stem Cells by Simultaneous Suppression of Multidrug Resistance and Antitopoisomerase II Defense. Acta Biomater (2015) 28:171–82. doi: 10.1016/j.actbio.2015.09.029

109. Saeki T, Nomizu T, Toi M, Ito Y, Noguchi S, Kobayashi T, et al. Dolipirdar Fumarate (MS-209) in Combination With Cyclophosphamide, Doxorubicin, and Fluorouracil for Patients With Advanced or Recurrent Breast Cancer. J Clin Oncol (2007) 25:411–7. doi: 10.1200/JCO.2006.08.1646

110. Saxena M, Stephens MA, Pathak H, Rangarajan A. Transcription Factors That Mediate Epithelial–Mesenchymal Transition Lead to Multidrug Resistance by Upregulating ABC Transporters. Cell Death Dis (2011) 2: e179–9. doi: 10.1038/cddis.2011.61

111. Kubiliute R, Januskevičiute R, Urbanavičiene R, Dainuaitė K, Drobinienė M, Ostanenkovas V, et al. Nongenotoxic ABCBl Activator Tetraphenylphosphonium Can Contribute to Doxorubicin Resistance in MX-1 Breast Cancer Cell Line. Sci Rep (2021) 11:6565. doi: 10.1038/s41598-021-86120-6

112. Singh A, Sett Jaim, EMT, Cancer Stem Cells and Drug Resistance: An Emerging Axis of Evil in the War on Cancer. Oncogene (2010) 29:4741–51. doi: 10.1038/onc.2010.215

113. Schulz A, Meyer F, Dubrovskas A, Borghmann K. Cancer Stem Cells and Radioresistance: DNA Repair and Beyond. Cancers (Basel) (2019) 11:E862. doi: 10.3390/cancers11060862

114. Zhao H, Duan Q, Zhang Z, Li H, Wu H, Shen Q, et al. Up-Regulation of Glycophosphatidylinositol (GPI) Stemness and EMT Phenotypes in Gmctineline-Resistant Pancreatic Cancer Cells. J Cell Mol Med (2017) 21:2055–67. doi: 10.1111/jcmm.13126

115. Versini A, Colombo L, Hiensch A, Gaillert P, Debieu S, et al. Carboxyterminally Silenced S100A8 Inhibits Breast Cancer Stem Cells by Lyosomal Iron Depletion. In Cancer Therapy. (2020) 26:4714–26. doi: 10.1002/ctm2.2000335

116. Maugeri-Saccà M, Bartucci M, De Maria R. DNA Damage Repair Pathways in Cancer Stem Cells. Mol Cancer Ther (2012) 11:1627–36. doi: 10.1158/1535-7163.MCT-11-1040

117. Sun Y, Wang Z, Na L, Dong D, Wang W, Zhao C. FZD5 Contributes to TNBC Proliferation, DNA Damage Repair and Stemness. Cell Death Dis (2020) 11:1060. doi: 10.1038/s41419-020-02832-3

118. Xiao J, Velasco-Velázquez MA, Wang M, Li Z, Rui H, Peck AR, et al. cCRR5 Governs DNa Damage Repair and Breast Cancer Stem Cell Expansion. Cancer Res (2018) 78:16577–71. doi: 10.1158/0008-5472.CAN-17-0915

119. Lee K-M, Giltnan JM, Balko JM, Schwarz LJ, Guirro-Jortino AL, Hutchinson KE, et al. MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. Cell Metab (2017) 26:633–647.e7. doi: 10.1016/j.cmet.2017.09.009

120. Noor R, Kundra GC. PO-285 Role of Tumour Associated Macrophages (TAMs) in Regulation of Cancer Stem Cell (CSCs) Enrichment in Breast Cancer. ESMO Open (2018) 3:A132. doi: 10.1136/esmoopen-2018-EACR25.316

121. Peng D, Tanikawa T, Li W, Zhao L, Vatan L, Szeliga W, et al. Myeloid-Derived Suppressor Cells Endow Stem-Like Qualities to Breast Cancer Cells Through IL6/STAT3 and NO/NOTCH Cross-Talk Signaling. Cancer Res (2020) 80:2491–506. doi: 10.1158/0008-5472.CAN-19-0247

122. Tanei T, Morimoto K, Shimazaki K, Kim SJ, Tanji Y, Taguchi T, et al. Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression With Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers. Clin Cancer Res (2009) 15:4234–41. doi: 10.1158/1078-0432.CCR-08-1479

123. Santamaria D, Gilkes DM, Chaturvedi P, Izen A, Semenza GL. Hypoxia-Inducible Factors Are Required for Chemotherapy Resistance of Breast Cancer Stem Cells. Proc Natl Acad Sci U S A (2014) 111:E5429–5438. doi: 10.1073/pnas.1421348111

124. Staudacher L, Cottu PH, Dieras V, Vincent-Salomon A, Guillaume MN, Escalup L, et al. Platinum-Based Chemotherapy in Metastatic Triple-Negative Breast Cancer: The Institut Curie Experience. Ann Oncol (2011) 22:848–56. doi: 10.1093/annonc/mdq461

125. Suda T, Jaffe ES, Schlossman SF. The monoclonal antibodies to the human cell-surface antigen CD55. J Immunol (1984) 132:641–9. doi: 10.4049/jimmunol.132.2.641

126. Canizo JA, Decker SM, Melenovsky V, et al. The Importance of Immune-Related Genes in Breast Cancer: An Analysis of the TCGA Data. Front Oncol (2018) 8:857. doi: 10.3389/fonc.2018.00857

127. Samanta D, Gilkes DM, Chaturvedi P, Izen A, Semenza GL. Hypoxia-Inducible Factors Are Required for Chemotherapy Resistance of Breast Cancer Stem Cells. Proc Natl Acad Sci U S A (2014) 111:E5429–5438. doi: 10.1073/pnas.1421348111

128. Sledge GW, Loehrer PJ, Roth BJ, Einhorn LH. Cisplatin as First-Line Chemotherapy for Metastatic Breast Cancer. J Clin Oncol (1988) 6:1811–4. doi: 10.1200/JCO.1988.6.12.1811

129. Xu H, Zhou Y, Li W, Zhang B, Zhang H, Zhao S, et al. Tumor-Derived Mesenchymal-Stem-Cell-Secreted IL-6 Enhances Resistance to Cisplatin via the STAT3 Pathway in Breast Cancer. Oncol Lett (2018) 15:9142–50. doi: 10.3892/ol.2018.8463

130. Thakur B, Ray P. Cisplatin Triggers Cancer Stem Cell Enrichment in Platinum-Resistant Cells Through NF-κB-TNFα-PIK3CA Loop. J Exp Clin Cancer Res (2017) 36:164. doi: 10.1186/s13046-017-0636-8

131. Sabatini MN, Delucia-Elci M, Capranico G. Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives. Int J Mol Sci (2018) 19:34380. doi: 10.3390/ijms191834380

132. CapelHńska T, Benyahia Z, Zampieri LX, Blackman MCNM, Sonveaux P. Metabolic and Non-Metabolic Pathways That Control Cancer Resistance to Anthracyclines. Semin Cell Dev Biol (2019) 98:181–91. doi: 10.1016/j.semcdb.2019.05.006

133. Jia D, Tan Y, Liu H, Ooi S, Li L, Wright K, et al. Cardamomin Reduces Chemotherapy-Enriched Breast Cancer Stem-Like Cells In Vivo and In Vivo. Oncotarget (2016) 7:7771–85. doi: 10.18632/oncotarget.5819

134. Du R, Liu B, Zhou L, Wang D, He X, Yu X, et al. Downregulation of Annexin A3 Inhibits Tumor Metastasis and Decreases Drug Resistance in Breast Cancer. Cell Death Dis (2018) 9:126. doi: 10.1038/s41419-017-0143-z
185. Pohlmann PR, Mayer IA, Mernaugh R. Resistance to Trastuzumab in Breast Cancer. *Clin Cancer Res* (2009) 15:7479–91. doi: 10.1158/1078-0432.CCR- 09-0636.

186. Nagata Y, Lan K-H, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN Activation Contributes to Tumor Inhibition by Trastuzumab, and Loss of PTEN Predicts Trastuzumab Resistance in Patients. *Cancer Cell* (2004) 6:117–27. doi: 10.1016/j.crcce.2004.06.022.

187. Burnett JP, Korkaya H, Ozounova MD, Jiang H, Conley SJ, Newman BW, et al. Trastuzumab Resistance Induces EMT to Transform HER2(+) PTEN(-) to a Triple Negative Breast Cancer That Requires Unique Treatment Options. *Sci Rep* (2015) 5:15821. doi: 10.1038/srep15821.

188. Seo AN, Lee HJ, Kim EL, Jang MH, Kim YJ, Kim JH, et al. Expression of Breast Cancer Stem Cell Markers as Predictors of Prognosis and Response to Trastuzumab in HER2-Positive Breast Cancer. *Br J Cancer* (2016) 114:1109– 16. doi: 10.1038/bjc.2016.101.

189. Saura C, Bendell J, Jerusalem G, Su S, Ru Q, De Buck S, et al. Phase Ib Study of Buparlisib Plus Trastuzumab in Patients With HER2-Positive Advanced or Metastatic Breast Cancer That Has progressed on Trastuzumab-Based Therapy. *Clin Cancer Res* (2014) 20:1935–45. doi: 10.1158/1078-0432.CCR-13-1070.

190. Dong C, Wu J, Chen Y, Nie J, Chen C. Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. *Front Pharmacol* (2021) 12:628690. doi: 10.3389/fphar.2021.628690.

191. Guerin M, Rezai K, Isambert N, Campone M, Autret A, Pakradouni J, et al. Downregulation of miRNA-200c Links Breast Cancer Stem Cells With Normal Stem Cells. *Cell* (2009) 138:592–603. doi: 10.1016/j.cell.2009.07.011.

192. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 Family and miR-205 Regulate Epithelial to Mesenchymal Transition by Targeting ZEB1 and SIP1. *Nat Cell Biol* (2008) 10:593–601. doi: 10.1038/ncb1722.

193. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C, et al. Let-7 Regulates Self-Renewal and Tumorigenicity of Breast Cancer Cells. *Cell* (2007) 131:1109– 23. doi: 10.1016/j.cell.2007.10.054.

194. Upton R, Banuelos A, Feng D, Biswas T, Kao K, McKenna K, et al. MicroRNA-21 Overexpression in Human Breast Cancer Is Associated With EMT and Sensitivity to PARP Inhibition in Breast Cancer by Regulating DNA Repair Genes. *Mol Cancer Res* (2012) 14:57–65. doi: 10.1158/1541-7786.MCR-12-0190.

195. Guerin M, Rezai K, Isambert N, Campone M, Autret A, Pakradouni J, et al. PI3K/HER2: A Phase Ib Study Evaluating Buparlisib in Combination With Lapatinib in Trastuzumab-Resistant HER2-Positive Advanced Breast Cancer. *Eur J Cancer* (2017) 86:28–36. doi: 10.1016/j.ejca.2017.08.025.

196. Tolaney S, Burris H, Gartner E, Mayer IA, Saura C, Maurer M, et al. Phase II/ II Study of Pilaralisib Plus Trastuzumab in Patients With HER2-Positive Advanced or Metastatic Breast Cancer. *Breast Cancer Res Treat* (2015) 149:151–61. doi: 10.1007/s10549-014-3248-4.

197. Chung SS, Giehl N, Wu Y, Vadgama JV. STAT3 Activation in HER2-Overexpressing Breast Cancer Promotes Epithelial-Mesenchymal Transition and Cancer Stem Cell Traits. *Int J Oncol* (2014) 44:403–11. doi: 10.3892/ijo.2013.2195.

198. Upton R, Banuelos A, Feng D, Biswas T, Kao K, McKenna K, et al. Combining CD47 Blockade With Trastuzumab Eliminates HER2-Positive Breast Cancer Cells and Overcomes Trastuzumab Tolerance. *Proc Natl Acad Sci USA* (2021) 118:e2026849118. doi: 10.1073/pnas.2026849118.

199. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib Plus Capecitabine for HER2-Positive Advanced Breast Cancer. *N Engl J Med* (2006) 355:2733–43. doi: 10.1056/NEJMoa064320.

200. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, et al. Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells Activation of MCL-1. *Cancer Res* (2009) 69:8871–8. doi: 10.1158/0008-5472.CAN-08-4900.

201. De Cola A, Volpe S, Budani MC, Ferracin M, Lattanzio R, Turdo A, et al. miR-205-5p Mediated Downregulation of ErbB/HER Receptors in Breast Cancer Stem Cells Results in Targeted Therapy Resistance. *Cell Death Dis* (2015) 6:e1823. doi: 10.1038/cddis.2015.192.

202. De Cola A, Lamoliniara A, Ianiut P, Rossi C, Iezzi M, Marchisio M, et al. MiR-205-5p Inhibition by Locked Nucleic Acids Impairs Metastatic Potential of Breast Cancer Cells. *Cell Death Dis* (2018) 9:821. doi: 10.1038/s41419-018-0854-9.

203. Lim Y, Wright JA, Attema JL, Gregory PA, Bert AG, Smith E, et al. Epigenetic Modulation of the miR-200 Family Is Associated With Transition to a Breast Cancer Stem Cell-Like State. *J Cell Sci* (2013) 126:Pt 12:122275. doi: 10.1242/jcs.122275.

204. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D, et al. Epigenetic Activation Contributes to Migration and Invasion by Inducing Epithelial-Mesenchymal Transition Consistent With Cancer Stem Cell Characteristics in MCF-7 Cells. *Cell Biochem Funct* (2012) 30:427–36. doi: 10.1007/s12275-011-1195-5.

205. Song SJ, Poliseno L, Song MS, Ala U, Webster K, Ng C, et al. MicroRNA-21 Antagonism Regulates Breast Cancer Stemness and Metastasis via TET- Family-Dependent Chromatin Remodeling. *Cell* (2013) 154:311–24. doi: 10.1016/j.cell.2013.06.026.
223. Cheng C-W, Yu J-C, Hsieh Y-H, Liao W-L, Shieh J-C, Yao C-C, et al. Increased Cellular Levels of MicroRNA-9 and MicroRNA-221 Correlate With Cancer Stemness and Predict Poor Outcome in Human Breast Cancer. Cell Physiol Biochem (2018) 48:2205–18. doi: 10.1159/000494261

224. Raha D, Wilson TR, Peng J, Peterson D, Yue P, Evangelista M, et al. The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation. Cancer Res (2014) 74:3579–90. doi: 10.1158/0008-5472.CAN-13-3456

225. Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, et al. Digoxin and Other Cardiac Glycosides Inhibit HIF-1 Synthesis and Block Tumor Growth. Proc Natl Acad Sci (2008) 105:19579–86. doi: 10.1073/pnas.0809763105

226. Lee K, Zhang H, Qian DZ, Rey S, Liu JO, Semenza GL. Acri Fux Function of ABC Transporters. BioMed Pharmaocot (2015) 72:37–43. doi: 10.1016/j.biopharma.2015.03.009

227. Wong CC-L, Zhang H, Gilkes DM, Chen J, Wei H, Chaturvedi P, et al. PI3K and Wnt Pathway Inhibition is a Synergistic Combination Against Triple Negative Breast Cancer. NPJ Breast Cancer (2017) 3:17. doi: 10.1038/ npjbreastcancer.2017.016–8

228. Zhou H, Yu C, Kong L, Xu X, Yan J, Li Y, et al. BSM, a Novel Specific Pan-PI3K Inhibitor, Preferentially Targets Cancer Stem Cells. Oncogene (2019) 38:3371–86. doi: 10.1038/s41388-018-0674-5

229. Jang G-B, Kim J-Y, Cho S-D, Park K-S, Jung J-Y, Lee H-Y, et al. Blockade of Wnt/B-Catenin Signaling Suppresses Breast Cancer Metastasis by Inhibiting CSC-Like Phenotype. Sci Rep (2015) 5:12465. doi: 10.1038/srep12465

230. Zhu R, Gires O, Zhu L, Liu J, Li J, Yang H, et al. Small-Molecule Inhibitor CWP232228 Preferentially Inhibits the Growth of Breast Cancer Stem-Like Cells. Cancer Res (2015) 75:1691–702. doi: 10.1158/ 0008-5472.CAN-14-2041

231. Yang Y, Hao E, Pan X, Tan D, Du Z, Xie J, et al. Gomisin M2 From Baizuan Suppresses Breast Cancer Stem Cell Proliferation in a Zebrafish Xenograft Model. Aging (2019) 11:8347–61. doi: 10.18632/aging.102323

232. Nickoloff BJ, Osborne BA, Miele L. Notch Signaling as a Therapeutic Target With Natural Products Toward Cancer Chemotherapy. J Antibiot (2012) 65:867–95. doi: 10.1093/ja/tas104

233. Cheng C-W, Yu J-C, Hsieh Y-H, Liao W-L, Shieh J-C, Yao C-C, et al. Dll1+ Sustains Bone Metastasis to Chemotherapy. Cancer Cell (2017) 32:731–47. doi: 10.1016/j.ccell.2017.11.002

234. Qiu M, Peng Q, Jiang I, Carroll C, Han G, Rymier I, et al. Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-directed Jagged1 sensitizes Aldehyde Dehydrogenase to Chemotherapy. Cancer Cell (2017) 32:731–47. doi: 10.1016/j.ccell.2017.11.002

235. Kumar S, Nandi A, Singh S, Regulapati R, Li N, Tobias JW, et al. Dll1+ Sustains Bone Metastasis to Chemotherapy. Cancer Cell (2017) 32:731–47. doi: 10.1016/j.ccell.2017.11.002

236. Shi Q, Peng Q, Jiang I, Carroll C, Han G, Rymier I, et al. Specific Inhibition of Notch1 Signaling Enhances the Antitumor Efficacy of Chemotherapy in Triple Negative Breast Cancer Through Reduction of Cancer Stem Cells. Cancer Lett (2013) 328:261–70. doi: 10.1016/j.canlet.2012.09.023

237. Shu Y, Guo R, Wei J, Zhou Y, Ji W, Liu J, et al. Effects of PI3K Inhibitor NVP-BKM120 on Overcoming Drug Resistance and Eliminating Cancer Stem Cells in Human Breast Cancer Cells. Cell Death Dis (2015) 6:e2020–0. doi: 10.1038/cddis.2015.363

238. Gargioli R, Cerliani JP, Escoll M, Antonio IM, Wandosell F. Cancer Stem Cell- Like Phenotype and Survival Are Coordinately Regulated by A Klf F and Oxal B in Macrophage. Stem Cells (2015) 33:646–60. doi: 10.1002/stem.1904

239. Kolev VN, Wright QG, Vidal CM, Ring JE, Shapiro IM, Ricono J, et al. PI3K/ mTOR Dual Inhibitor VS-5854 Preferentially Targets Cancer Stem Cells. Cancer Res (2015) 75:446–55. doi: 10.1158/0008-5472.CAN-14-1223
261. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, Kulp AN, et al. Saha and Lukong BCSCs in Drug Resistance.

262.Zhong G, Qin S, Townsend D, Schulte BA, Tew KD, Wang GY. Oxidative Stress Induces Senescence in Breast Cancer Stem Cells. Biochem Biophys Res Commun (2019) 514:1204–9. doi: 10.1016/j.bbrc.2019.05.098

263. Vlashi E, Lagadec C, Vergnes L, Reue K, Frohnen P, Chan M, et al. Metabolic Differences in Breast Cancer Stem Cells and Differentiated Progeny. Breast Cancer Res Treat (2014) 146:525–34. doi: 10.1007/s10549-014-3051-2

264. El-Sahli S, Hua K, Sulaiman A, Chambers J, Li L, Farah E, et al. A Triple-Drug Therapy of Cytotoxic T-Lymphocyte Responses In Vivo After Vaccinations With Peptide-Pulsed Dendritic Cells. Blood (2000) 96:3102–8. doi: 10.1182/blood.V96.9.3102.h003310_250_3108

265. Li J, Huang K, Zhang Y, Kupfer G, Zhao Q. Chimeric Antigen Receptor T Cell Therapy: Challenges and Prospects. Acta Pharm Sin B (2021) 11:1721–39. doi: 10.1016/j.apsb.2020.12.015

266. Sun R, Wang M, Wang M, Yu X, Guo J, Sun T, et al. Metabolic Reprogramming in Triple-Negative Breast Cancer. Front Oncol (2020) 10:428. doi: 10.3389/fonc.2020.00428

267. Ashton TM, McKenna WG, Kunz-Schughart LA, Higgins GS. Oxidative Phosphorylation as an Emerging Target in Cancer Therapy. Clin Cancer Res (2018) 24:2482–90. doi: 10.1158/1078-0432.CCR-17-5707

268. Reyes-Castellanos G, Masoud R, Carrier A. Mitochondrial Metabolism in Breast Cancer. Biomedicines (2020) 8:E270. doi: 10.3390/biomedicines8080270

269. Huang Y, Zhou Y, Huang K-H, Li Y, Fang X, An L, et al. EGFR-Specific CAR-T Cells Trigger Cell Lysis in EGFR-Positive TNBC. Aging (Albany NY) (2019) 11:1054–72. doi: 10.18632/aging.102510

270. Pindiprolu SKS, Krishnamurthy PT, Chintamaneni PK, Karri VVSR. Engineering Precision Nanoparticles for Drug Delivery. Sci Transl Med (2019) 11:eaav0696. doi: 10.1126/scitranslmed.aav0696

271. Pindiprolu SKSS, Krishnamurthy PT, Chintamaneni PK, Karri VVSR. Nanocarrier Based Approaches for Targeting Breast Cancer Stem Cells. Artif Cells Nanomed Biotechnol (2018) 46:885–90. doi: 10.1080/21699410.2017.1366337

272. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering Precision Nanoparticles for Drug Delivery. Nat Rev Drug Discov (2021) 20:101–24. doi: 10.1038/s41573-020-0090-8

273. Li J, Huang K, Zhang Y, Kupfer G, Zhao Q, Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy for Solid Tumors: Lessons Learned and Strategies for Moving Forward. J Hematol Oncol (2018) 11:122. doi: 10.1186/s10064-018-0568-6

274. Liang Y, Tang H, Kong Y, Xie X, Chen J, Song C, et al. LGR5 Promotes Breast Cancer Progression and Maintains Stem-Like Cells Through Activation of Wnt/B-Catenin Signaling. LGR5 Activation in Breast Cancer Stem Cells. Stem Cells (2015) 33:2913–24. doi: 10.1002/stem.2083

275. Li J, Li W, Huang K, Zhang Y, Kupfer G, Zhao Q. Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy for Solid Tumors: Lessons Learned and Strategies for Moving Forward. J Hematol Oncol (2018) 11:122. doi: 10.1186/s10064-018-0568-6

276. Goodarzi N, Amini M, Gahremani MH, Ayatkhoo F, Ostad SN, Dinarvand R. Hyaluronic Acid-Drug Conjugates of Doxetaxel and Metformin to Target Cancer Cells and Cancer Stem Cells: Synthesis and Characterization. J Control Release (2013) 172:e59. doi: 10.1016/j.jconrel.2013.08.122

277. Elsher JD, Krishnadas DK, Lucas KG. Dendritic Cell Vaccines: A Review of Recent Developments and Their Potential Pediatric Application. Hum Vaccin Immunother (2016) 12:2232–9. doi: 10.1080/21645515.2016.1179844

278. Gaborizhov DL, Corak J, Ciernik IF, Kavanaugh D, Carbone DP. Decreased Antigen Presentation by Dendritic Cells in Patients With Breast Cancer. Clin Cancer Res (1997) 3:843–90.
